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Abstract 
Background 
The 21st century has seen antibiotic resistance rise to be a major public health concern. The 
O’Neill report in 2016 reiterated the importance of antibiotic resistance and proposed many 
actions, including strengthening surveillance systems, the development of rapid 
diagnostics, and investment in new classes of antibiotics and alternatives. 
Urinary tract infections (UTIs) are one of the most common infections diagnosed in the 
United Kingdom with uropathogenic Escherichia coli (UPEC) the most common cause. It 
is thought that the main reason why UPEC is so successful at causing UTIs, is its 
expression of a wide range of virulence factors including adhesins, capsules, toxins and 
iron-acquisition systems. Overuse of beta-lactam antibiotics to treat UTIs has led to 
selection for extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae, a 
major cause of antibiotic resistant urinary tract infections (UTIs). The prevalence of ESBL 
producing UTIs has dramatically risen, limiting treatment options. The most common 
ESBL types seen today are CTX-M, TEM, OXA and SHV. The emergence and spread of 
these types of ESBLs is thought to be through the horizontal transmission of antibiotic 
resistance plasmids IncL/M, IncF, IncN and IncI1. These conjugative plasmids have been 
directly linked to major outbreaks of antibiotic resistance.  
Standard detection methods for ESBL-producing UTIs are time-consuming, with disputed 
accuracy. Patients are often treated empirically with broad-spectrum antibiotics. Reducing 
the time spent on broad-spectrum antibiotics by prescribing a more appropriate treatment, 
increases the favorability of the outcome of the patient and shortens the stay in hospital.  
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Aims 
This study had three aims: to investigate the prevalence of ESBLs and the relationship 
between plasmids and ESBLs in Leicestershire; to develop a rapid, accurate method to 
detect ESBLs (TEM, SHV, OXA, and CTX-M) using real-time PCR and to investigate the 
effect of cranberry (Cysticlean®) on the expression of 10 virulence genes. 
Methods 
A total of 236 uropathogenic E. coli ESBL-producing isolates were collected from the 
Leicester Royal Infirmary. This study identified ESBL genes (CTX-M, SHV, TEM and 
OXA) and multiple CTX-M gene subtypes by multiplex PCR. A multiplex PCR-based 
replicon typing assay identified IncFIA, IncI1, IncL/M, IncN and IncFII. A real-time PCR 
assay was designed using amplicon melting analysis and the Plexor system to detect the 
ESBL family.  
A CTX-M-producing E.coli isolate was treated with the cranberry extract Cysticlean®. 
Taqman qRT-PCR was used to detect the relative expression of the virulence genes SAT, 
USP, ChuA, SoxS, KPSM, TraT, RecA, IdfB and HcaT and the antibiotic resistance gene 
CTX-M. 
Results 
ESBL genes were identified as follows: CTX-M (71.6%), OXA (7.6%), TEM (3.8%) and 
SHV (3.8%) with multiple genes detected in 10.2% of isolates. CTX-M-1 (84.1%) was the 
most frequently detected CTX-M subtype. Replicon typing results were as follows: IncL/M 
(29.2%), IncN (14.4%), IncI1 (5.1%), IncFII (27.5%) and IncFIA (23.3%). A combination 
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of IncL/M, IncFII and IncFIA was the most common at 9.8%. A positive correlation 
between CTX-M and all plasmids except IncI1 was found.   
The qualitative real-time PCR assay correctly identified 97.7% isolates tested, with a 
sensitivity and specificity of 98.7% and 83.3% respectively. The positive predictive value 
was 97.5% and the negative predictive value was 90.9%.  
Results from the qRT-PCR assay showed that Cysticlean® was able to significantly reduce 
the expression of all the genes investigated. 
Conclusions 
This is the first study to analyse the prevalence of uropathogenic ESBLs in Leicestershire. 
The ability to rapidly and accurately detect ESBL genes is an important step in improving 
antimicrobial stewardship and reducing morbidity and mortality as a result of ESBL-
producing pathogenic infections. The ability to reduce the expression of critical virulence 
factors, could lead to the development of alternatives to antibiotics. 
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1 Introduction 
1.1 Urinary Tract Infection 
Escherichia coli (E.coli) is often part of the normal flora of the gastrointestinal flora of both 
humans and animals. In most circumstances, the presence of E.coli in the gastrointestinal 
tract is beneficial to the host, by promoting homeostasis and outcompeting harmful 
bacteria. When freed from the confines of the gastrointestinal tract, where E.coli rarely 
causes infection, even non-pathogenic E.coli strains can cause infection and strains can take 
on a more pathogenic nature. These strains are still able to colonise the gastrointestinal 
tract, but also have the ability to disseminate into other areas of the host such as the blood, 
central nervous system and the urinary tract (Bien, et al., 2012). 
Urinary tract infections (UTIs) effect approximately 150 million people annually 
worldwide, thus becoming one of the most common infections seen in man (Dash, et al., 
2018). UTIs are a substantial cause of morbidity, especially in females, elderly men and 
infants (Foxman, 2003). The complications of UTI can be serious, involving recurrent 
infections, pyelonephritis with sepsis, pre-term birth and renal damage in children. Other 
consequences include the potential for antibiotic resistance due to frequent antibiotic usage 
and Clostridium difficile colitis (Foxman, 2003). Whether or not a person develops a UTI 
depends on anatomical factors, host defence mechanism integrity and the level of virulence 
of the infecting pathogen (Nicolle, 2002).  
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1.1.1 UTI Classification 
UTIs can be classified as either uncomplicated or complicated. Uncomplicated infections 
generally effect patients that are otherwise healthy, including no urinary tract abnormalities 
(Svanborg, 1997). Complicated UTIs are associated with aspects that compromise either 
the urinary tract, or host defences, or both. This includes urinary obstruction, neurological 
disease leading to urinary retention, immunosuppression and renal failure (Svanborg, 
1997). Urinary tract infections are commonly related with catheters. Catheter-associated 
UTIs (CAUTIs) have been related to increased morbidity and mortality and frequently 
cause secondary bloodstream infections. CAUTI risk factors include female gender, older 
age, diabetes and prolonged catheterisation (Svanborg, 1997). UTIs are also categorised 
depending on the site of infection. Infection of the bladder is termed cystitis, infection of 
the kidney is termed pyelonephritis, and infection of the urine is bacteriuria (Bien, et al., 
2012). 
Bacteriuria can be asymptomatic, and this does not normally require treatment. 
Additionally, in some cases colonisation of the pathogen can prevent the infection of a 
more virulent pathogen (Bien, et al., 2012). 
More than 80% of UTIs, including asymptomatic bacteriuria, are caused by uropathogenic 
E. coli (UPEC) strains (Trautner, 2003) (Darouiche, 2001) (Hull, 2000). 
The majority of community-acquired and a large portion of nosocomial UTIs, are caused by 
these UPEC strains. UPEC infections cause substantial medical costs and increase 
morbidity and mortality worldwide (Bien, et al., 2012).  
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1.1.2 Infection and Colonisation Mechanisms 
In order for pathogens to successfully infect a host, they must adhere to host cells and 
colonise tissues whilst overcoming host defences (Foxman, 2003). The bladder epithelium 
comprises three main cell types: umbrella cells, intermediate cells and basal cells (Wiles, et 
al., 2008). UPEC bind to umbrella cells via uroplakins, that protect the tissue from 
damaging chemicals in urine by forming a crystalline array in the apical membrane (see 
figure 1-I) (Wiles, et al., 2008). Uroplakins are not the only place that UPEC can bind, 
α3β1 integrins, expressed at the surface of uroepithelial cells, can also function as receptors 
for UPEC (Wiles, et al., 2008). Colonisation of the urinary tract by UPEC, may lead to 
ascension towards the bladder, leading to cystitis, causing painful, frequent and urgent 
urination. From the bladder, UPEC can travel via the ureters to the kidney, causing 
pyelonephritis which can result in irreversible kidney damage and even death (Scholes, 
2005). 
1.1.3 UPEC Virulence Factors 
Virulence factors increase the capacity of bacteria to cause an infection. UPEC strains can 
acquire a number of virulence factors, which aid them in colonizing and persisting in the 
urinary tract. Virulence genes are commonly located on mobile genetic elements such as 
pathogenicity islands, transposons, bacteriophages or plasmids and are generally acquired 
by DNA horizontal transfer.  
In general, the more important virulence factors implicated in the successful infection and 
persistence in the urinary tract are those that are associated with the surface of the bacterial 
cell, and those that are secreted and exported to the site of action (Bien, et al., 2012). More 
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specifically, the main virulence factors associated with UPEC are adhesins, capsules, toxins 
and iron-acquisition systems (Muller, 2016). Research suggests that adhesions, or fimbriae, 
are the most important UPEC virulence factors and determine the pathogenicity of the 
bacterial strain. These adhesive organelles promote the attachment of bacterial cells to host 
tissues within the urinary tract. Fimbriae contribute to the virulence of the bacterial strain 
by activating cell signaling pathways in both the bacteria and the host, enabling bacterial 
product delivery to host tissues and potentially most importantly, by promoting bacterial 
invasion of host tissues.  
1.1.4 Adhesins 
1.1.4.1 Type 1 Fimbriae 
The virulence determinant of type 1 fimbriae is poorly understood in human pathology, 
however in animal models, it has been shown to enhance bacterial survival, stimulate 
inflammation of the mucosal lining and to promote biofilm growth. The difficulty in 
determining the role of type 1 fimbriae in humans is due to the fact that they are expressed 
in both pathogenic and non-pathogenic strains at the same frequency. In both pathogenic 
and non-pathogenic strains, type 1 fimbriae bind to uroplakin Ia and IIIa, located at the top 
of the fimbriae, via a FimH adhesion subunit (Bien, et al., 2012). The interactions between 
the FimH- α3β1 integrin results in the activation of the RHO-family GTPases, via actin 
arrangement, leading to the invasion of bacteria into the cell (see figure 1-I) (Flores-
Mireles, 2015). This then leads to the activation of signaling pathways, leading to 
molecular phosphorylation events involved in invasion and apoptosis (see figure 1-I). In 
addition, Tamm-Horsfall Protein is released into the urine by kidney cells, acting as a FimH 
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receptor. This can lead to the obstruction of UPEC’s capability to interact with the receptor, 
reducing the ability to colonise the urinary tract. Once UPEC has navigated inside the host 
cell, it can then undermine host defenses and withstand antibiotic treatment (Bien, et al., 
2012). However UPEC releases lipopolysaccharide (LPS), which can then be detected by 
Toll-like receptor 4 (TLR4) (see figure 1-I). This stimulates the production of cyclic AMP 
(cAMP) caused be adenylyl cyclase 3 (AC3) activation, which can cause the subsequent 
exocytosis of UPEC (see figure 1-I) (Bien, et al., 2012). This mechanism of innate 
immunity is disrupted by UPEC through evasion into the cytoplasm. When in the 
cytoplasm, UPEC proliferates into intracellular bacterial communities (IBCs) (see figure 1-
I) (Flores-Mireles, 2015). These IBCs mature, causing the dispersal of bacteria, leading to 
the invasion of additional host cells, spreading the infection and beginning the IBC cycle 
once again (see figure 1-I) (Flores-Mireles, 2015). During IBC formation, UPEC develops 
into filamentous cells that upon emerging from their dormant state, are resistant to killing 
by neutrophils, leading to the colonization of other cells (Flores-Mireles, 2015). 
An alternative mechanism of evading the immune response is the formation of quiescent 
intracellular reservoirs (QIRs) (see figure 1-I) comprising of 4-10 bacteria encased in F-
actin. In this state, QIRs do not replicate and can persist dormant for several weeks, 
eventually becoming active and progressing into the bladder lumen as transitional cells 
differentiate to umbrella cells (Flores-Mireles, 2015).  
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Figure 1-I Virulence factors of uropathogenic Escherichia coli that contribute to urinary tract infections.  Various 
virulence factors contribute to the successful colonization, invasion and persistence of uropathogenic Escherichia 
coli (UPEC) in the bladder. The role of these virulence factors is described in the text. lipopolysaccharide (LPS) Toll-like 
receptor 4 (TLR4), cyclic AMP (cAMP), adenylyl cyclase 3 (AC3), intracellular bacterial communities (IBCs), quiescent 
intracellular reservoirs (QIRs), α-haemolysin toxin (HlyA), Cytotoxic necrotizing factor 1 (CNF1), basal cell adhesion 
molecule (BCAM) Figure adapted from (Flores-Mireles, 2015).  
1.1.4.2 Capsules 
Other virulence factors situated on the surface of the bacterial cell include the capsule and 
the lipopolysaccharide, an integral component of the bacterial cell wall. The main function 
of the capsule is to protect the bacterium from host defenses such as engulfment by 
phagocytes and the bactericidal effect produced by the complement system, via a 
polysaccharide structure. One of the ways that capsules do this is through molecular 
mimicry of tissue components, thus preventing an immune response. The 
lipopolysaccharide activates the inflammatory portion of the host response by inducing 
nitric oxide and cytokine production.  
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1.1.4.3 Iron Acquisition Systems 
The urinary tract is naturally limited in iron (Bien, et al., 2012). Therefore, in order to be 
successful in persisting in the urinary tract, UPEC uses iron scavenging or siderophore 
systems to be able to grow in urine. These systems are composed of two parts: a 
siderophore for iron binding and a membrane receptor that transports the iron into the cell. 
It is thought that one of the reasons that UPEC is so successful in the urinary tract is the 
production of several siderophores, such as aerobactin and yersinabactin (Flores-Mireles, 
2015).  
1.1.4.4 Flagella 
Flagella are organelles that are responsible for the motility of bacteria and the mediation of 
the interaction between UPEC and epithelial cells. It has been suggested that the flagella 
can be associated with pyelonephritis, participating in the ascension of UPEC from the 
bladder to the kidneys. 
1.1.4.5 Toxins 
1.1.4.5.1 HlyA 
Toxins are another virulence factor that are important in UTIs and may also cause the 
activation of the inflammatory response, leading to UTI symptoms. α haemolysin (HlyA) is 
a lipoprotein that is believed to be one of the most significant virulence factors associated 
with UTI. These toxins are thought to be widespread in the gram-negative pathogenic 
community and approximately 50% of renal complications due to pyelonephritis are caused 
by HlyA. It is thought that this is due to induction of endothelial damage and renal 
vasoconstriction and permanent renal scarring is commonly associated with HlyA. When 
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HlyA is at a high concentration, it is capable of lysing erythrocytes and host cells, leading 
to the passage of UPEC across mucosal barriers, damaging the host cells, allowing the 
acquisition of iron and other host nutrients (see figure 1-I). At low concentrations, HlyA 
still has many abilities, particularly the apoptosis of host immune cells, renal cells and also 
the exfoliation of urinary tract epithelial cells (Bien, et al., 2012). 
1.1.4.5.2 CNF1 
Another important secreted toxin is cytotoxic necrotizing factor 1 (CNF1) and its main 
purpose is to bind to the receptor basal cell adhesion molecule (BCAM) on host cells (see 
figure 1-I). This binding stimulates the activation of RHO GTPases, leading to membrane 
ruffling (see figure 1-I). Activation of RHO GTPases also activates the pro-survival 
pathway, leading to the prevention of apoptosis of infected cells and the expansion of 
UPEC cells (see figure 1-I) (Bien, et al., 2012). 
1.2 Host Response  
As the urinary tract is normally a sterile environment, the presence of bacteria such as 
UPEC will trigger the host innate immune response. This response includes the production 
of inflammatory mediators such as cytokines which results in the recruitment of neutrophils 
into the infected area to ingest bacteria and to release enzymes that destroy bacteria. The 
host inflammatory response also causes the exfoliation of epithelial cells infected by 
bacteria and the generation of antimicrobial compounds such as reactive nitrogen and 
oxygen species (Bien, et al., 2012). 
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1.2.1 The Urinary Tract 
In order to keep the urine sterile, the urinary tract has a number of defences. The main way 
the urinary tract clears bacteria is through the bulk flow of urine in the bladder. Further 
defence is provided by the secretion of glucosamine by transitional cells, this forms a 
mucin layer that prevents bacterial adherence. The urinary tract environment has a low pH 
and contains salts, urea and organic acids that naturally limit bacterial survival. The urinary 
tract also produces defensins, in response to the presence of bacteria. Defensins are 
peptides that have the ability to cause cell death in bacteria by increasing cell permeability 
via disrupting cell membrane function. 
1.2.1.1 Exfoliation of Infected Cells  
One of the most important parts of the inflammation process is the exfoliation of infected 
cells via a disruption of urothelial integrity. Infected host cells are then excreted. This 
process is FimH dependent and occurs via an apoptosis-like pathway. 
1.2.1.2 Inflammation 
If UPEC is able to evade the exfoliation process and adhere to the uroepithelium, the 
presence of bacteria activates the innate and adaptive immune responses including the 
production of cytokines, neutrophil recruitment and local tissue damage. 
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1.3 Antimicrobial Agents 
1.3.1 Definition 
Traditional antibiotics are natural metabolic products fungi and bacteria, that are able to 
inhibit or kill bacteria. Today most of the natural antibiotics in clinical use are then 
modified, to produce semi-synthetic antibiotics, improving their antibacterial or 
pharmacologic properties. Others are completely synthetic, such as sulphonamides and 
quinolones.  
1.3.2 Discovery and Development 
During the first decade of 20th century, Paul Ehrlich was the first to propose the 
relationship between microbial pathogens and drugs, as his experiments led to the 
arsphenamines for the treatment of syphilis. The present era of antimicrobial chemotherapy 
began in 1935, with the discovery of the sulphonamides by Gerhard Domagk. In 1929, 
penicillin was discovered by Alexander Fleming and he proposed that penicillin could be an 
effective chemotherapeutic agent. However, Fleming was unable to exploit this clinically 
and it was left to Florey and Chain to purify penicillin and prepare it for clinical use in 1940 
(Aminov, 2010). The years of the 1950s and 1970s are considered the golden era of 
antibiotic discovery, with several novel classes identified. However, with no new classes 
discovered since then underlines the need to tackle antibiotic resistance to the drugs 
currently available. 
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1.4 Modes of Action of Antibiotics 
Antimicrobial drugs have several mechanisms that lead them to inhibit or destroy bacteria. 
These include:   
1. The interference of bacterial cell wall synthesis. For example, β-lactam antibiotics 
such as Cephalosporins and Carbapenams 
2. The interference of protein synthesis: For example, Aminoglycosides, Macrolides 
and Tetracyclines 
3. Interference with DNA synthesis. For example, Quinolones and Metronidazole.  
4. Inhibition of RNA synthesis. For example, Rifamycins.  
5. Inhibition of metabolic pathways. For example, Trimethoprim and 
Sulfamethoxazole.  
6. Disruption of membrane structure. For example, Polymyxins (Etebu & Arikekpar, 
2016). 
1.5 Beta-Lactam Antibiotics 
1.5.1 Structure  
β-Lactams are one of the three largest classes of antibiotics and includes penicillins, 
cephalosporins, carbapenems, and monobactams (Fisher, et al., 2005). β-Lactams have 
been amongst the most successful drugs for the treatment of bacterial infections caused by 
numerous species for the past 70 years (Coleman, 2011). Clearly, this class of antibiotics 
has played a vital role to the preservation of human health, as stated by Fisher et al (2005). 
Their name comes from the presence of a β-lactam ring in their structure (Figure 1-II); this 
ring is vital for antimicrobial activity (Worthington & Melander, 2013). β-Lactams exert 
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their antibiotic effects by disrupting cell wall synthesis by inhibiting the normal function of 
the family of enzymes known as penicillin-binding proteins (PBP). Usually PBP would 
form cross-links between adjacent glycan chains in the bacterial cell wall (Figure 1-III). 
However, β-Lactam antibiotics are able to mimic the natural D-Ala-D-Ala substrate of the 
PBP, thus preventing the formation of cross-links between adjacent glycan chains (Figure 
1-III) (Tipper & Strominger, 1965).  
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Figure 1-II beta-lactam antibiotic structure. All beta-lactam antibiotics contain the same core 4-member “beta-lactam” 
ring (Left).  The beta-lactam ring structure is similar to the shape of the terminal D-Ala-D-Ala peptide substrate for 
penicillin binding proteins or cell wall transpeptidases that form covalent bonds between different peptidoglycan chains 
during cell growth. The 4-ring structure and associated side groups result in tight binding to the active site of Penicillin 
Binding Proteins, inhibiting enzyme activity, and consequently preventing cell wall formation (See figure 1-III). 
Modification of the structure of the naturally occurring penicillins resulted in the development of both synthetic penicillin 
analogs, as well as new families of beta-lactams such as cephalosporins (Right). Chemical structures were drawn using 
chem-space.com. Figure adapted from (Clarkson, 2015). 
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1.5.2 Mechanism of action 
 
Figure 1-III Mechanism of action of beta-lactam antibiotics. Penicillin Binding Proteins (PBP) play a key role in 
forming a rigid cell wall that protects the bacterial cell from osmotic forces. Penicillin Binding Proteins (PBP) form 
Pentaglycine Chains between adjacent glycan chains, this catalytic reaction also results in the removal of a terminal D-
alanine residue (Black arrow) from one of the peptidoglycan precursors. The structural resemblance of the Beta-lactam 
ring, in Beta-lactam antibiotics like penicillin, to the D-Ala-D-Ala substrate for the PBP, allows the Beta-lactam ring to 
bind tightly to the PBP. The binding of a Beta-lactam antibiotic to PBP prevents the formation of Pentaglycine Chains 
(vertical red lines), this results in a cell wall vulnerable to osmotic forces that may cause cell rupture. Figure adapted from 
(Clarkson, 2015). 
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1.6 Resistance to Antimicrobials 
Whenever a new antibiotic is introduced, antibiotic resistance typically occurs within a few 
years. As most antibiotics are derived from microbial or fungal products, this is to be 
expected. The overuse and misuse of antibiotics creates selective pressure for those bacteria 
that are intrinsically (naturally) resistant or those that have acquired resistance, usually 
through horizontal gene transfer. 
Resistance to antibiotics generally occurs via one of four mechanisms. 1) Bacteria may 
possess genes that encode enzymes that inhibit antibiotics, before they can take effect e.g. 
β-lactamases. 2) Bacteria may possess efflux pumps that prevent the antibiotic from 
binding to the target site by eliminating the antibiotic from the cell. 3) Bacteria may have 
the ability to alter the targets used by antibiotics. 4) Bacteria may possess mutation in genes 
that regulate porins, limiting the access of antibiotics (Kapoor, et al., 2017).    
1.6.1 Intrinsic Resistance  
Resistance of a bacteria to an antibiotic may be as a result of a general natural evolution, 
that is not related to any particular antibiotic class. An example of this is the outer 
membrane of Gram-negative bacteria, gives a natural resistance to some antibiotics 
(Kapoor, et al., 2017). 
 
 
 36 
1.6.2 Acquired Resistance  
Acquired resistance causes the most concern. Rather than the development of naturally 
occurring resistance to antibiotics, bacteria can develop resistance through the acquisition 
of resistance determinants via conjugation, transduction and transformation. This can occur 
not only between strains of the same species, but also between different species and genera. 
This process combined with mutations and selection via antibiotic pressure, enable bacteria 
to rapidly adapt to the introduction of a new antibiotic (Kapoor, et al., 2017). 
1.7 Extended-Spectrum Beta Lactamases 
Beta-lactam antibiotics are the most frequently used antibiotic worldwide, therefore 
bacterial resistance has continued to rise since their introduction due to a permanent 
selective force for resistance mechanisms (Pitout, et al., 1997; Bush & Macielag, 2010). 
This is an example of accelerated evolution following the Darwinian paradigm, whereby 
the most adapted to the environment will survive and pass on their genes to the next 
generation (Canton, 2012). Extended-spectrum β-lactamases (ESBLs) are mainly plasmid-
encoded enzymes that are able to inactivate a variety of β-lactam antibiotics, including 
penicillins, 2nd-, 3rd- and 4th-generation cephalosporins and monobactams (e.g. 
aztreonam) (Zurfluh, 2015). However, ESBLs are generally susceptible to clavulanic acid 
(a beta-lactamase inhibitor), sulbactam and tazobactam (Shaikh, et al., 2015). 
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Figure 1-IV β-lactamases confer resistance against β-lactam antibiotics. The synthesis of β-lactamases is the most 
common mechanism that imparts drug resistance to β-lactam antibiotics (Hall et al, 2003). β-lactamases hydrolyse the 
beta-lactam ring, this prevents the antibiotic from inhibiting cell wall synthesis. Extended-Spectrum Beta-Lactamases 
(ESBLs) are enzymes produced by several types of gram-negative bacteria (E coli, Klebsiella, Enterobacter, Proteus) that 
enable bacteria to have resistance to all penicillins, cephalosporins, and monobactams, but do not affect sensitivity to 
carbapenems. Chemical structures were drawn using chem-space.com. Figure adapted from (Clarkson, 2015).  
1.7.1 ESBL Classification 
There are two distinct classification systems for beta-lactamases: the Ambler molecular 
classification and the Bush–Jacoby–Medeiros functional classification. The protein 
homology of the beta-lactamases is used to determine the Ambler scheme of four classes 
(Shaikh, et al., 2015). The four classes can then be differentiated further, classes A, C and D 
are serine beta-lactamases and class B are metallo-beta-lactamases. In contrast, the Bush–
Jacoby–Medeiros functional scheme takes advantage of the functional properties of the 
beta-lactamase enzymes to classify them, for example their substrate and inhibitor profiles 
(Shaikh, et al., 2015). The Ambler Scheme shall be used from here onwards. 
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1.7.2 Important ESBLs 
Clinically, the most important class A ESBLs include: TEM, SHV and CTX-M (Rahman, 
et al., 2018). The highest diversification and quickest evolution is within the CTX-M 
family of class A. The most important class D beta-lactamase is the OXA-type. The TEM, 
SHV and OXA type ESBL enzymes originate from point mutations within the plasmid-
mediated TEM-1, TEM-2, SHV-1 and OXA-10 enzymes. ESBLs of the TEM and SHV-
type were most frequently found in the 80’s and 90’s and are mainly associated with 
hospital outbreaks of Klebsiella pneumoniae (Canton, 2012). To this date (September 
2018), there have been over 172 different CXT-M enzymes discovered, classified into five 
groups: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25, based on their amino 
acid composition (Rahman, et al., 2018). Being part of the class A ESBLS, it would be 
assumed that CTX-M producing enzymes would be related to TEM and SHV groups. 
However, this is not the case. Each of the CTX-M groups presents a 94% amino acid 
homology within the group itself and 90% homology between the other CTX-M groups 
(Shin, 2015). The CTX-M family is unlike other ESBLs in that it includes a complex and 
non-homologous group of enzymes. It has been suggested by phylogenetic analysis that the 
CTX-M enzymes did not originate by mutations from plasmid mediated enzymes but 
through chromosomal mobilization of bla genes from the Kluyvera species through mobile 
genetic elements. Like the other ESBLs, after these genes had been incorporated, the CTX-
M enzymes evolved through punctual mutations due to antibiotic selective pressure. This 
brought about the variants of CTX-Ms that can be seen today (Canton, 2012). Within the 
CTX-M family of ESBLs, CTX-M-15 and CTX-M-14 are the most important, as they can 
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be found almost everywhere all over the world. In the UK the CTX-M-15 type is the most 
prominent (Canton, 2012). The first report of a CTX-M positive isolate was from Japan in 
1986. The ESBL was originally called TOHO-1 but later changed to CTX-M due to its 
ability to resist cefotaxime. During the first decade or so after it was discovered, general 
dissemination and infrequent nosocomial outbreak was reported, mainly from Argentina. 
Over the last 15 years, CTX-M producing E.coli has become a major cause of community-
onset UTI all over the world, creating the so-called “CTX-M pandemic” (Shin, 2015). 
Within the CTX-M family, CTX-M-15 has become the most important and widely 
distributed CTX-M enzyme. It was first discovered in India in 2001. The CTX-M-15 
enzyme belongs to the CTX-M-1 cluster of ESBLs, thought to originate from the CTX-M-3 
family of genes, differing by one amino acid substitution – an Asp to Gly change at 
position 240. This results in an increased resistance to Ceftazidime, due to increased 
catalytic activity (Peirano, 2010).  
1.7.3 Discovery and Evolution of ESBL Groups 
1.7.3.1 CTX-M  
Phylogenetic trees of the CTX-M family suggest that the family can be differentiated into 
five clusters (Naas, et al., 2007; Bonnet, 2004). Each of these clusters has been linked to the 
chromosomal bla genes found in the kluyvera species of bacteria. The kluyvera species is a 
normal part of the intestinal flora of humans, found in low amounts and is associated with 
urinary tract, skin and soft tissue opportunistic infections. It is also found in water, soil, 
sewage and animal food products as free-living organisms. The ancestor of the CTX-M-1 
cluster has been suggested to be the chromosomal bla gene kluC, from the kluyvera 
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cryocrescens. The origin of the CTX-M-2 cluster is said to be from the kluyvera ascorbata 
species. CTX-M-8, CTX-M-9 and CTX-M25 originated from three chromosomal bla genes 
from kluyvera georgiana, kluG, kluY and blaCTX-M-78. The CTX-M-74 and CTX-M-75 
have been found to only have a single amino acid change from CTX-M-2 but may be 
considered as a new cluster, showing that the ESBLs are still evolving and diverging 
(Decousser, et al., 2001; Humeniuk, et al., 2002).  
This being said, several questions about the lineage of the CTX-M family remain 
unanswered. When comparing the phylogenetic trees of CTX-M and 16s rDNA sequences 
of Kluyvera species, it is revealed that the evolutionary relationships do not correlate 
consistently (Canton, 2012).  
1.7.3.2 OXA 
The OXA-type are ESBLs and are so named because of their oxacillin-hydrolyzing abilities 
(Shaikh, et al., 2015). OXAs are beta-lactamases that facilitate resistance to ampicillin, 
cephalothin, oxacillin and cloxacillin, however are resistant to the beta-lactamase inhibitor 
clavulanic acid and are generally encoded by plasmids. The first OXA ESBL is believed to 
have been discovered in Turkey, from P. aeruginosa isolates in a single hospital (Shaikh, et 
al., 2015).  
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1.7.3.3 TEM 
When first discovered in 1965, the TEM beta-lactamases substrate and inhibition profiles 
were comparable to SHV-1, for example TEM-1 is only capable of hydrolyzing penicillins 
and first generation cephalosporins. Since 1965, the TEM beta-lactamases have evolved 
and diverged, variants now have increased activity against extended spectrum 
cephalosporins, for example TEM-3 (Shaikh, et al., 2015).  
1.7.3.4 SHV 
The SHV beta- lactamases have been suggested to have originated from Klebsiella spp. 
Like the TEM beta lactamases, the SHV family has evolved from resistance to broad-
spectrum penicillins such as ampicillin, tigecycline and piperacillin but not to the oxyimino 
substituted cephalosporins to conferring an extended spectrum resistance today (Shaikh, et 
al., 2015). 
1.8 ESBL-Producing Urinary Tract Infections 
It has recently become apparent that ESBL producing bacteria can be found not only in 
symptom producing patients, but also in asymptomatic human carriers. Increased risk of 
ESBL producing community-onset urinary tract infections can be due to many risk factors 
including multiple previous urinary tract infections, renal pathology, extended antibiotic 
use (especially cephalosporins), hospilisation/nursing home care, liver pathology, diabetes 
and international travel (Fournier, 2013; Zurfluh, 2015).  Serious infection can be linked to 
length of hospital stay, admittance to an intensive care unit and catheterization. These 
infections in particular correlate with increased mortality, morbidity and healthcare cost 
(Wintermans, 2013; Shin, 2015). Those patients that suffer from a symptomatic UTI are 
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usually treated with antibiotics. Antibiotic treatment of UTI has been associated with long-
term alteration of normal micro-biota of the vagina. Long-term antibiotic treatment for 
recurrent UTI is related to the development of antibiotic resistance (Al-Mayahie, 2013).  
1.9 Epidemiology  
1.9.1 Difficulties in Acquiring Epidemiology Data 
ESBL epidemiology is very complicated and there are a number of issues to consider. The 
geographical area (country), the reservoir (humans, environment, companion animals, 
livestock etc.) and location of acquired infection (hospital or community) should all be 
taken into account when conducting prevalence studies (Shaikh, et al., 2015).  
1.9.2 Global Epidemiology 
1.9.2.1 Europe 
There are still reports in Europe of new TEM and SHV types emerging. With regards to 
CTX-M, different subtypes are common in different countries. CTX-M-9 is common in 
Spain, whilst CTX-M-3 is common in Eastern Europe. Overall in Europe, the CTX-M-1 
group (including CTX-M-15) is the most widespread and has been associated with isolates 
found in the community (Shaikh, et al., 2015).  
In the UK, the Surveillance Atlas of Infectious Diseases reports the level of E.coli resistant 
to third generation cephalosporins in 2016 to be 9.2%. This is actually a decline in 
incidence since 2013. In comparison, the incidence level in Bulgaria in 2016 was 41.6%. 
Other problematic areas in Europe include Cyprus (30.2%), Italy (29.8%) and Slovakia 
(29.7%) as can be seen in figure I-V. 
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Figure 1-V Map of surveillance information for third-generation Cephalosporin resistance in E. coli. Dataset provided by 
ECDC based on data provided by WHO and Ministries of Health from the affected countries. Surveillance information 
contains percentages of E. coli isolates that are resistant to third-generation Cephalosporins in Europe, in 2016 (European 
Centre for Disease Prevention and Control, 2017). 
1.9.2.2 Asia and the Indian Subcontinent 
It has only been recently that we have begun to understand the degree to which ESBL-
producing Enterobacteriaceae is effecting parts of Asia and the Indian subcontinent, and 
the incidence of ESBLs is continuing to rise (Shaikh, et al., 2015). In India specifically, 
three medical centers reported that 66% of third generation cephalosporin resistant 
Enterobacteriaceae harbored CTX-M-15. Ten other centers in India reported ESBL rates of 
70% within Enterobacteriaceae (Shaikh, et al., 2015).  
It has been suggested that several of the most successful clones that harbor ESBLs have 
originated from Asia (Shaikh, et al., 2015). The main factors in the development of 
resistance include inadequate sewage practices, insufficient quality of drinking water and a 
lack of regulation with regards to the sale of antibiotics over the counter and the over 
prescription of antibiotics be doctors (Shaikh, et al., 2015).  
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1.9.2.3 The Middle Eastern Countries 
Incidences of 26% for ESBL-producing Klebsiella pneumoniae isolates have been seen in 
Saudi Arabia, whereas a prevalence of 26.5% for E. coli and 43% for Klebsiella has been 
reported in Iran (Tawfik, et al., 2011). A different study in Iran reported that 42.1% of the E. 
coli isolates derived from patients with clinical symptoms of UTIs were of ESBL-
producing (Ebrahim-Saraie, et al., 2018). 
1.9.2.4 Africa 
In Tanzania, hospitals have described rates of ESBL-producing isolates in Klebsiella 
pneumoniae as high as 64%. An orphanage in Mali reported that 100% of the children 
carried ESBL-producing Enterobacteriaceae (Shaikh, et al., 2015). Likewise, in 
Madagascar, it was observed that 10% of non-hospitalised patients carried ESBLs. It has 
been suggested that poverty is an important risk factor for carriage of ESBLs (Shaikh, et al., 
2015). A systematic search review that used Twenty-six studies (409 215 isolates) from 13 
African countries ESBL-producing isolates from a urinary source varied from 1.5% to 
22.8% (Tansarli, et al., 2014). Combined, these reports may indicate that the prevalence in 
Africa may be increasing. 
1.9.2.5 America 
It was estimated in 2001 that 5.3% of E.coli in America was ESBL-producing. A more 
recent study in 2009 in a cancer center revealed 9% of E.coli isolates were ESBL-
producers. 
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As can be seen here, there is substantial global variation in the incidence of antibiotic 
resistance. This variation has been linked to the usage of antibiotics. Some countries have 
been working hard to reduce their antibiotic consumption, whereas others have seen a rapid 
rise in usage. Despite the variation in antibiotic consumption and resistance rates, it is clear 
that antibiotic resistance is a concern worldwide. 
1.10 The One Health Approach 
The One Health Approach to tackling antibiotic resistance outlines the importance of 
understanding the relationship between humans, animals and the environment when it 
comes to the spread of antibiotic resistance genes. The main aim of the One Health 
Approach is to ensure that antimicrobial agents continue to be effective by developing 
policies that promote the responsible use of antimicrobial agents. This involves 
investigating the possible transmission between these three vectors and creating suitable 
antibiotic stewardship and other policies for reducing resistance rates in isolates found in 
humans, animals and what is inevitably released into the environment (Conrad, et al., 
2013). 
1.11 Spread of ESBLs 
The rise and ease of international travel of both humans and animals has increased the 
opportunity for antibiotic resistance determinants to spread worldwide. As previously 
mentioned, bacteria can share and acquire genes that increase their antibiotic resistance. 
This can create new antibiotic resistant strains at a much faster rate than before (Sleeman, et 
al., 2017). A summary of this mechanism can be seen in figure I-VIII. 
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1.11.1 Mobile Genetic Elements 
Mobile genetic elements are sequences of genetic material that can change places on a 
chromosome, and be exchanged between chromosomes, between bacteria, and even 
between species (Frost, et al., 2005). Plasmids are an example of this. Tracking mobile 
genetic elements between bacterial species and locations allows for the study and prediction 
of evolution. 
1.11.2 Insertion Sequences  
Insertion sequences (IS) are similar to mobile genetic elements, in that they can move from 
one location to another, however they are limited to the bacterial chromosome. Insertion 
sequences often appear in the middle of a gene, and this can disable the expression of that 
gene by interrupting the coding sequence. They can also inactivate the expression of genes 
downstream of the insertion sequence in the same operon, owning to the presence of 
termination signals of transcription and translation (Griffiths, et al., 2000). 
It has been found that there is a link between CTX-M genes and the surrounding genetic 
elements. As mentioned previously, the theory is that CTX-M genes originated from the 
Kluyvera species. It is thought that this occurred due to mobilisation of CTX-M genes by 
insertion sequences and possibly bacteriophages. Insertion sequences have many functions, 
but with relation to CTX-M, they are responsible for the over-expression of CTX-M genes, 
leading to a high resistance phenotype. Some insertion sequences are adjacent to integron 
structures, which in turn are integrated into transposition units, called supra-structures. 
Successful or high-risk clones often contain these supra-structures, which are incorporated 
within conjugative plasmids. In addition to this, supra-structures can also perform as 
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evolutionary units and units of selection (Canton, 2012). Integrons which contain multiple 
gene cassettes are called super-intergrons. Many gene cassettes contain genes which code 
for antibiotic resistance, therefore benefitting their host (Ravi, 2014). Mobilisation of CTX-
M genes has been demonstrated experimentally due to insertion sequences located 
upstream. The promoter Pout increases the expression of CTX-M by effecting upstream 
insertion sequences. It is thought that this had a role in the selection and dissemination of 
CTX-M. Upstream sequences that have been identified include ISEcp1, ISCR1, IS10 and 
IS26. The most common insertion sequence by far is ISEcp1, originally found upstream of 
CTX-M-15 in 1999. It has also been found in all other clusters of ESBLs, apart from CTX-
M-8 (Canton, 2012).  
1.11.3 Spacer Sequences  
A spacer sequence is a region of non-coding DNA between genes. Spacer sequences, in 
relation to the genetic distance between ISEcp1 and CTX-M, is mentioned in multiple 
studies (see figure 1-VI). It is well documented that the spacer sequence between ISEcp1 
and CTX-M has an influence on Cephalosporin MIC. The distance of spacer sequence 
ranges between CTX-M clusters. In CTX-M-1, the spacer sequence is between 48 and 
127bp in length. There is a strong homology between spacer sequences in the CTX-M-1 
cluster (Canton, 2012; Ma, et al., 2011).  
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Figure 1-VI The relationship between spacer sequence and antibiotic susceptibility. The length of the spacer sequence 
between the insertion sequence ISEcp1 and the gene cassete CTX-M-1 is variable. This example shows spacer sequences 
of 127 bp (top) and 48bp (bottom). The larger the spacer sequence, the higher the susceptibility of the isolate to Beta-
lactam antibiotics. Figure adapted from (Zong, 2010). 
 
1.11.4 Plasmids  
Plasmids are a type of mobile genetic element that are able to integrate directly into the 
chromosome or persist in the bacterial cytoplasm (see figure 1-VII). Plasmids are key 
agents of change in bacterial populations. All bacteria, including E.coli, transport plasmids. 
A plasmid is a self-replicating double stranded, circular or linear genetic element and vary 
in size from a few to more than several hundred kb. Plasmids usually regulate their rate of 
replication to control their concentration within the cell, maintaining their characteristic 
copy number throughout the cell line. There is a minimal part of the plasmid that must 
replicate with the characteristic copy number of the parent plasmid, called the basic 
replicon. These replicons incorporate the ori, but also contain specific replication initiator 
protein (REP) encoding genes. REPs bind to the ori and their regulating factors. Plasmids 
spread through the promotion of conjugation between bacteria of different genera and 
kingdoms. Conjugation involves transferring plasmids from a donor to a recipient cell. This 
is a contact–dependent, energy-driven system. There are plasmids that are unable to transfer 
themselves via conjugation, these can be transferred with the use of a helper plasmid. 
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Plasmids are selfish genetic elements, as they are able to facilitate their own replication. 
This being said, most plasmids also carry genes that are beneficial to their bacterial host. It 
is quite often beneficial to carry certain plasmids as they carry a selectable phenotype, for 
instance virulence of some kind, or antibiotic resistance, along with insertion sequences, 
transposons and class 1 integrons. Plasmids can carry more than one gene for selectable 
advantage. For example, resistance plasmids can also carry virulence factors such as 
bacteriocins and cytotoxins. Likewise, virulence plasmids have also been known to carry 
resistance genes such as those that code for ESBLs. Under antibiotic and infectious 
pressure, these traits may facilitate the successful spread of certain plasmid types between 
different bacteria and geographical locations (Moran, 2015). It is this spread that has made 
the tracking of plasmids so important. Tracking plasmids helps to understand how plasmids 
are disseminated so widely and quickly. Tracking is not as easy as it seems, as there are 
many different types of plasmid, and each type of plasmid has many variations that need to 
be taken into account (Moran, 2015). A plasmid classification scheme was designed by 
Datta and Hedges in 1971 based plasmid incompatibility (Inc). Plasmid Inc is determined 
by the stability of the plasmid during conjugation. Two plasmids of the same Inc group 
cannot be conjugated into the same cell stably. There are currently 27 recognised Inc 
groups within Enterobacteriaceae. Plasmid typing on a molecular scale was first proposed 
in 1988 by Couturier, involving replicons of each Inc types and southern blot 
hybridisations. It wasn’t until 2005 that a PCR-Based Replicon Typing (PBRT) scheme 
was introduced. This uses multiplex PCR to detect the Inc groups of the major plasmid 
types occurring in Enterobacteriaceae (Carattoli, 2005). Many papers have discussed the 
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importance of plasmids in the spread of ESBL genes, especially CTX-M (Carattoli, 2011). 
It appears that CTX-M is primarily associated with plasmids of Inc group FII and have 
been termed as “epidemic resistance plasmids”. FII plasmids are narrow host-range and are 
characterised by a low-copy number in the host bacteria. They are able to easily acquire 
resistance genes and transfer amongst bacteria, making them a major concern. It is thought 
that FII plasmids contain replicon types that help speed up the rate at which evolution and 
diversification of plasmids occurs. It has also been suggested that these plasmids were 
already incorporated into many Enterobacteriaceae, meaning that they were already well 
suited to these bacteria before acquisition of resistance genes occurred. This explains the 
rapid dissemination of CTX-M genes within Enterobacteriaceae. Also, these plasmids may 
have already contained genes coding for resistance other than beta-lactamases, contributing 
to the co-selection process during their evolution. It is thought that these genes will persist 
and evolve over many generations, giving rise to new CTX-M variations and yet wider 
dissemination (Canton, 2012).  
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Figure 1-VII Dissemination of antibiotic resistance genes and production of resistant bacteria.   The diagram 
summarises how bacteria can acquire, incorporate, express and spread genes from their environment. This process is 
exacerbated by antibiotic misuse which results in bacteria utilising increasing antibiotic pressure as a method of survival. 
Over time this can result in the development of multi-drug resistant bacteria which may spread throughout the 
environment. Figure adapted from (Davies, 1994). 
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1.11.5 Addiction Systems  
Plasmids produce addiction systems (or toxin-antitoxin) to facilitate the maintenance of 
plasmids during replication. Addiction systems are small genetic elements that, when not 
present, can cause bacterial cell death and/or cell arrest. The plasmid produces both a toxin 
and an anti-toxin. The anti-toxin prevents the toxin’s deleterious activity. Therefore, when 
the plasmid is removed from the cell, the toxin produced previously is able to cause 
replication or segregation errors. Therefore, it is in the cell’s best interest to maintain the 
presence of these plasmids (Hayes, 2003). It is thought that CTX-M producing plasmids 
use many addiction systems to ensure that the plasmids are maintained in multiple strains 
of bacteria, facilitating their dissemination (Tamang, 2014). On the other hand, plasmid 
addiction systems represent potential antibacterial targets, resulting in the development of 
novel drugs to counteract plasmids contains genes coding for multi-drug resistance 
(Tamang, 2014).  
1.12 ESBL Detection in Clinical Practice 
In order to detect a UTI, a midstream, clean-catch urine sample is taken from a patient 
suspected of having cystitis (Schmiemann, et al., 2010). Cystitis is then determined as the 
presence of ≥103 bacteria/ml. Clinicians can also screen samples by colorimetric dipstick 
testing for nitrites and leukocyte esterase, however, there have been many reports of false-
negative results. Therefore, further microscopic urinalysis and culture is performed 
(Schmiemann, et al., 2010). Once in the clinical microbiology laboratory, a sample is then 
cultured on agar plates and those that grow ≥104 cfu/ml of a single or predominant species 
of uropathogenic bacteria are considered culture positive (Davenport, et al., 2017). 
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Chromogenic agar can help to distinguish between E.coli, Staphylococcus saprophyticus 
and Enterococcus species (D'Souza, et al., 2004). The time taken from urine collection to 
identification of the causative pathogen is normally 18-30 hours. 
1.12.1 Defining Antibiotic Resistance  
One of the significant roles of the clinical microbiology laboratory is the determination of 
antibiotic susceptibility, taking an additional 24-48 hours depending on the pathogen and 
the method used. In the UK, the Health Protection Agency (HPA) provides guidelines for 
the detection of ESBLs in Enterobacteriaceae and recommend antibiotic susceptibility 
testing with either 1 mg/L of cefpodoxime, 1 mg/L each of cefotaxime, ceftazidime, 
ceftriaxone, or aztreonam, followed by confirmatory tests with both cefotaxime and 
ceftazidime in combination with clavulanate at a concentration of 4 lg/mL. This method 
shows a high sensitivity and specificity, 94% and 98% respectively (Shaikh, et al., 2015). 
Some automation has been carried out in some laboratories, with high-throughput 
instruments such as the Microscan Walkaway (Beckman Coulter), Phoenix Automated 
Microbiology System (BD), and Vitek 2 (BioMérieux). These instruments can improve 
turnaround time to around 10-16 hours (Eigner, et al., 2005; Thomson, et al., 2007).  
1.12.2 Genotypic Detection  
Genotypic detection of ESBLs generally involves PCR amplification, and in the case of 
TEM and SHV genes, subsequent sequencing to distinguish between ESBL and non-ESBL 
genes. Recently, several studies have depicted various new approaches to rapidly detect 
ESBLs (Davenport, et al., 2017). 
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1.13 Treatment  
Antibiotics are currently the recommended treatment for symptomatic UTI including 
trimethoprim sulfamethoxazole, ciprofloxacin and ampicillin (Hooton, 1997). However, 
increasing rates of resistance has led to the use of carbapenems instead. The use of 
carbapenems as an alternative treatment has led, as expected, to an increased prevalence of 
carbapenems producing multi-drug resistant Enterobacteriaceae. (Vigil et al., 2010 and 
Gqunta. 2015).  
1.13.1  Alternative Treatments 
1.13.1.1 Treatment with Cranberry 
Cranberry fruit has been suggested as an alternative for the treatment and prevention of UTI 
(Fu, et al., 2017). Cranberries are mostly composed of water, but also contain organic acids, 
fructose, a high level of vitamin C, flavonoids, anthocyanidins, catechins and triterpenoids 
(Guay, 2009). There are many species of cranberry, however the American cranberry 
(Vaccinium macrocarpon) is the only one that has been shown to have a role in UTI. It is 
thought that this is due to a reduction in bacterial adhesion to the urinary tract wall. 
Cranberries are most commonly taken as whole berries, juices (usually only 10-25% 
cranberry) and capsules. Juices are the most common (Vostalova, et al., 2015). Pure 
cranberry juice is unpalatable due to its acidity. It is recommended that people consume 
cranberry either before a meal, or two hours after and drinking excess water is generally 
necessary, particularly after drinking dehydrated juices. Inhibition of adherence by 
cranberry has also been seen in multidrug resistant UPEC strains. The combination of 
cranberries and antibiotics has also been tested. In a combination of β-lactams and 
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cranberry, a modest delay in absorption was seen, however overall absorption was not 
affected. The biosafety of cranberries has been tested, with no biochemical or 
haematological alterations found and it has been suggested that cranberry has up to an 8-
hour window that it decreases UPEC adherence after consumption (Hisano, et al., 2012). 
1.14 Summary  
UTIs are one of the most common bacterial infections. Both the numerous uropathogens, 
which encode a wide range of virulence factors, and the spread of antimicrobial resistance 
threaten the only effective treatment option available — antibiotics. Moreover, high rates of 
recurrent UTIs suggest that antibiotics are not an effective therapy for all UTIs.  
The CTX-M family of genes has become an important area of study in recent years. It is 
thought that the CTX-M genes originated from the Kluyvera spp, however there is some 
contradictory research with regards to this. Since its origination, CTX-M has spread 
considerably, creating the so-called “CTX-M epidemic”. Successful dissemination has been 
associated with the co-existence of CTX-M and other resistance determinants, leading to 
multi-drug resistance. CTX-M genes are closely linked to IncFII plasmids, thought to be 
present in multiple Enterobacteriaceae before the evolution of CTX-M genes, one 
explanation as to how this particular type of ESBL was able to spread so rapidly. However, 
research is conflicted as to the correlation between the presence of CTX-M genes and the 
level of virulence factors. It is clear that current recommended methods for the detection of 
CTX-M positive isolates are not sufficient in current circumstances. Rapid methods such as 
Real Time-PCR have been suggested due to their greater sensitivity and the fact that 
identification is at the genetic level. Whichever method is used, it is clear that the CTX-M 
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family of genes will remain an important issue for some time, and their evolution and 
further dissemination needs to be closely monitored. 
1.15 Aims  
1. Complete genotypic study to establish the prevalence of ESBLs and the CTX-M 
family within samples collected from the Leicester Royal Infirmary (LRI).  
2. Complete plasmid replicon typing of samples from LRI. 
3. Develop a rapid detection method for ESBLs in urinary tract infection.  
4. Analyse the effect of a natural product on the expression levels of virulence genes 
produced by E. coli using quantitative reverse transcriptase-PCR (RT-qPCR). 
1.16 Thesis Layout 
This thesis is manuscript based and has been organized into five chapters. Chapter 1 
introduces the topic and outlines the rationale and research objectives. Chapter 2 is a 
manuscript describing the prevalence of ESBLs in the Leicestershire area. Chapter 3 
describes the development of a rapid qualitative real-time PCR based method to detect 
ESBLs. Chapter 4 is a manuscript showing results of an analysis of the effect of cranberry 
on the expression of virulence genes in E.coli. Chapter 5 is the overall discussion and 
conclusion of the thesis. Appendix A outlines the experimental development and rationale. 
 
 
 57 
 
 
Chapter 2: 
Genotypic Identification of Extended-
Spectrum Beta-Lactamase (ESBL)-Producing 
Enterobacteriaceae from Urinary Tract 
Infections in the Leicestershire Area, United 
Kingdom: A One Health Prospective 
 58 
  
 
 
 
 
 
 
 
Statement of Contributions of Joint Authorship 
Reid, R:  (Candidate) 
Writing and compilation of manuscript, carrying out of experiments, data 
analysis, preparation of tables and figures 
 
 
Samarasinghe, S: (Supervisor) 
Assisted with manuscript compilation and editing. 
 
 
The journal paper referred to below has been adapted for use within a 
thesis. 
 59 
Genotypic Identification of Extended-Spectrum Beta-Lactamase (ESBL) - Producing 
Enterobacteriaceae from Urinary Tract Infections in the Leicestershire Area, United 
Kingdom: A One Health Prospective 
 
Ruth Reid1 and Shivanthi Samarasinghe1#  
 
Running title: Genotypic Identification of ESBLs in Leicestershire, UK 
 
 
 
1Molecular Microbiology, School of Allied Health Sciences, Faculty of Health & 
Life Sciences, Hawthorn Building, The Gateway, De Montfort University, Leicester, 
LE1 9BH, United Kingdom. 
 
 
#Address correspondence to: Dr Shivanthi Samarasinghe, Molecular Microbiology, 
The Gateway, De Montfort University, Leicester, LE1 9BH, 
ssamarasinghe@dmu.ac.uk, +44 (0)116 207 8870. 
  
 60 
Abstract 
Aims 
Urinary tract infections (UTIs) are one of the most common infections diagnosed in the 
United Kingdom (UK). The prevalence of extended-spectrum-beta-lactamase (ESBL) 
producing UTIs has dramatically risen, limiting treatment options. The emergence and 
spread of ESBLs is thought to be through the horizontal transmission of antibiotic 
resistance plasmids IncL/M, IncF, IncN and IncI1. These conjugative plasmids have been 
described as important vectors and directly linked to major outbreaks of antibiotic 
resistance. This study aimed to investigate the prevalence of ESBLs in Leicestershire, UK 
and their relationship with antibiotic resistance plasmids. 
Methods 
A total of 236 ESBL producing uropathogenic Enterobacteriaceae isolates were obtained 
from the Leicester Royal Infirmary (Leicestershire, UK). ESBL production was confirmed 
phenotypically via the MAST ID double disc synergy test. ESBL-producing genes (CTX-
M, SHV, TEM and OXA) were identified by multiplex PCR. The CTX-M family was then 
further characterised into (CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25) by 
multiplex PCR. The relationship between ESBL-producing genes and plasmid type was 
then investigated by multiplex PCR-based replicon typing to detect IncFIA, IncI1, IncL/M, 
IncN and IncFII.  
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Results 
ESBL genes were identified as follows: CTX-M (71.6%), OXA (7.6%), TEM (3.8%) and 
SHV (3.8%). Multiple resistance genes were detected in 16% of isolates. CTX-M genes 
were identified as follows: CTX-M-1 (84.1%), CTX-M-9 (12.5%), CTX-M-25 (1.7%), 
CTX-M-8 (1.1%) and CTX-M-2 (0.6%). Replicon typing results were as follows: IncL/M 
(29.2%), IncN (14.4%), IncI1 (5.1%), IncFII (27.5%) and IncFIA (23.3%). A combination 
of IncL/M, IncFII and IncFIA was the most common at 9.8%. A positive correlation 
between CTX-M and all plasmids except IncI1 was found.   
Conclusion 
CTX-M producing Enterobacteriaceae are associated with multiple plasmids, which can be 
linked to its rapid spread across the world. Prevalence studies help to inform policy about 
antibiotic stewardship and resistance evolution, aiming to reduce resistance levels in the 
future.  
 
Keywords:  Extended-spectrum beta-lactamases, multiplex PCR, antibiotic 
resistance, CTX-M, urinary tract infection, replicon typing, One Health Approach.  
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2 Introduction  
Urinary tract infections (UTIs) are one of the most common bacterial infectious diseases 
diagnosed in outpatients in the UK. Of the causes of UTIs, uropathogenic Escherichia coli 
(UPEC) is the most prevalent (Al-Assil., 2013).  Risk factors for acquiring a UTI include 
previous exposure to 3rd and 4th generation cephalosporins and fluroquinolones; 
hospitalisation; old age; female gender; recurrent UTI infection, diabetes and 
catheterisation (Al-Assil., 2013).  
The most common type of resistance in UTIs is beta-lactamase production, resulting in 
extended-spectrum beta-lactamase (ESBL) producing bacteria (Lupo, 2013). These bacteria 
produce enzymes that can hydrolyse oxyimino-cephalosporins (ceftriaxone, cefotaxime, 
ceftazidime and cefepime) and monobactams (aztreonam) but not cephamycins and 
carbapenems. Based on their amino acid sequence, these enzymes have been classed into 
four groups – A – D (Lupo, 2013).  Class A enzymes have been shown to be the most 
clinically important, due to their link to treatment failure, increased morbidity, mortality 
and healthcare costs. The most important class D beta-lactamase is the OXA-type. There 
are 3 main families of class A: TEM, SHV and CTX-M. While TEM, SHV and OXA 
ESBLs arise via substitutions in strategically positioned amino acids from the natural 
narrow-spectrum TEM-1/-2, SHV-1 and OXA-10 β-lactamases, all CTX-M variants 
demonstrate an ESBL phenotype (Lupo, 2013). Previously, most ESBLs detected were of 
the TEM/SHV group. From the 1990’s the CTX-M family became increasingly more 
common, and now it is reported to be the most prevalent type of ESBL detected at present 
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worldwide (Lupo, 2013). The worldwide dissemination and dramatically increasing 
prevalence of the CTX-M family of ESBLs is due to the selective pressure caused by the 
over-use, and more importantly, mis-use of the beta lactam antibiotics (Lupo, 2013). 
Risk factors for an ESBL-producing UTI are: recent hospilisation; treatment with 
3rd generation Cephalosporins; old age (over 65); diabetes; recurrent UTI; indwelling 
catheters and female gender (Dash, et al., 2018).  It has been reported that ESBL-producing 
isolates are more likely to be associated with significant pyuria, suggesting that ESBLs are 
more likely to cause a clinically significant UTI (Qiao, et al., 2017; Wragg, et al., 
2017). Although most ESBL-producing UTIs are acquired in the community, a hospitalised 
patient is approximately 4 times more likely to be diagnosed with an ESBL-producing UTI 
(Dash, et al., 2018).  
The significant increase in movement of livestock and agricultural produce and human 
travel has facilitated the rapid amalgamation and dissemination of antibiotic resistance 
genes (Bengtsson-Palme, et al., 2018). The emergence and spread of antibiotic resistance 
determinants is often through horizontal transmission of mobile genetic elements such as 
plasmids (Roshani, et al., 2017). 
It is the large, low-copy, self-transmitting resistance conjugative plasmids that are 
increasingly threatening the efficacy of antibiotics for Gram-negative infections; and have 
been directly linked to antibiotic resistance outbreaks. Conjugative plasmids can carry more 
than one gene for a selectable advantage such as antibiotic resistance genes and virulence 
factors such as bacteriocins and cytotoxins. Under antibiotic and infectious pressure, these 
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traits may facilitate the successful spread of certain plasmid types between different 
bacterial hosts and geographical locations (Moran, 2015). This results in ESBL-producing 
isolates that can show resistance to other types of antibiotics, leading to multidrug 
resistance (MDR). MDR limits treatment options, resulting in less favourable outcomes for 
patients (Shaikh, et al., 2015). Surveillance of the spread of these plasmids can help track 
antibiotic resistance determinants and phylogenetic and comparative analysis can identify 
the origin and evolution of these genes (Bennett, 2008). 
Many papers have discussed the importance of plasmids in the spread of blaCTX-M genes, 
especially CTX-M-1 (Carattoli, 2011; Agyekum, et al., 2016; Bevan, et al., 2017; Bonnet, 
2004; Canton, 2012; Zurfluh, et al., 2015). Studies have suggested that CTX-M is primarily 
associated with plasmids of IncF, IncL/M, IncN and IncI1 and these have been termed as 
“epidemic resistance plasmids” in Enterobacteriaceae (Wang, et al., 2013). It is suggested 
that these plasmids are successful as they likely provide virulence and antimicrobial 
resistance determinants, such as ESBL-production, that contributes to the fitness of the 
bacterial host. They also guarantee their survival and stability in the host through the 
production of several addiction systems, such as toxin-antitoxin systems. Therefore, they 
are maintained without the need for selective pressure of antibiotic treatment. This could 
explain the rapid dissemination of CTX-M genes within Enterobacteriaceae (Carattoli, 
2009). 
IncF plasmids are narrow host-range and are characterised by a low-copy number in the 
host bacteria. They are able to easily acquire resistance genes and transfer amongst 
bacteria, making them a major concern. It is thought that IncF plasmids contain replicon 
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types that help speed up the rate at which evolution and diversification of plasmids occurs 
(Mathers, et al., 2015). It has also been suggested that these plasmids were already 
incorporated into many Enterobacteriaceae, meaning that they were already well suited to 
these bacteria before acquisition of resistance genes occurred (Carattoli, 2009). All IncI1 
plasmids contain genes for the type IV pili in their plasmid backbone structure. This has 
been suggested to contribute to the adhesive and invasive properties of shiga-toxigenic E. 
coli (Zurfluh, et al., 2015). IncL/M are broad-host range plasmids and reports have 
suggested that the IncL/M family are mostly responsible for the dissemination of CTX-M-3 
in Eastern Europe, France, Belgium and Korea (Carattoli, 2009). It has been observed that 
the IncL/M plasmid has a higher plasmid copy number than IncF co-purified in the same 
host, suggesting that IncL/M could induce a higher resistance level in its host due to 
increased gene dosage (Adamczuk, et al., 2015).  
IncN are also broad-host range plasmids and some studies suggest that IncN is specific to 
the food chain and it has been confirmed that these plasmids are circulating among food 
producing animals (Zurfluh, et al., 2014). CTX−M−1 has frequently been reported on the 
broad host-range replicon plasmids IncI and IncN, which appear to have a reservoir in 
animals. In particular, a high prevalence among E. coli of the avian faecal ﬂora has been 
found (Zurfluh, et al., 2014). 
Realising the major health concern that antibiotic resistance presents, the world health 
organisation (WHO) developed a global strategy for the containment of antimicrobial 
resistance in 2001. This involved monitoring the prevalence of ESBLs in the UK, and other 
countries all over the world. Prevalence studies help to inform policy on infection 
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prevention and antibiotic stewardship. They allow monitoring of evolution of antibiotic 
resistance genes and prediction of possible future evolution (World Health Organization, 
2001). The importance of surveillance was reiterated in the O’Neill report in 2016 where it 
was suggested that all antibiotic prescriptions should be informed by up-to-date 
surveillance information (O'Neill, 2016). 
The One Health Approach to tackling antibiotic resistance outlines the importance of 
understanding the relationship between humans, animals and the environment when it 
comes to the spread of antibiotic resistance genes. This involves investigating the possible 
transmission between these three vectors and creating suitable antibiotic stewardship and 
other policies for reducing resistance rates in isolates found in humans, animals and what is 
inevitably released into the environment (Robinson, et al., 2016). Prevalence studies are an 
important way of monitoring the transmission of resistance determinants between vectors, 
and whether stewardship and other measures are working effectively (O'Neill, 2016). 
It has been known for some time that companion animals can act as a reservoir for 
antibiotic resistance determinants. Pets can not only be a source of contamination, but due 
to close contact with their owners, could be contaminated by human bacteria (Melo, et al., 
2018). Contributing factors include the growing population of both humans and companion 
animals and urban development, leading to increased interactions among people and 
animals (Sleeman, et al., 2017).  
The contribution of food production to the global antibiotic resistance problem has been 
questioned, as there are not that many reports of animal-associated infections in humans. 
Due to the way that antibiotics are used in food production, at sub-therapeutic 
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concentrations and with long exposure, this creates the ideal conditions for antibiotic 
resistance determinants to be acquired and subsequently transmitted to humans via human-
adapted pathogens through farmers, contaminated food or the environment. Therefore, the 
misuse of antibiotics in food production can be a driver of antibiotic resistance that needs to 
be monitored and rectified (Prestinaci, et al., 2015).  
The environmental element of the One Health Approach is the least well understood. 
Antibiotics are used in plant protection and environmental bacteria serve as a source for 
antibiotic resistance in a similar manner to that of animals, which can be incorporated into 
pathogens that infect animals and humans. The problem is exacerbated by the discarding of 
waste into the environment that contains antibiotic resistance genes and antibiotic residues 
from the pharmaceutical industry, livestock and hospitals. They are therefore providing a 
resistome, as a mixture of resistant and non-resistant, pathogenic and non-pathogenic 
bacteria that can exchange plasmids and therefore antibiotic resistance genes such as 
ESBLs between one another (Zurfluh, et al., 2015). This is more likely to be a significant 
problem in developing countries, due to issues with environmental legislation and 
enforcement. 
The aim of this study is to identify the prevalence of the different ESBL types in 
Leicestershire by multiplex PCR. PCR-based replicon typing will be used to investigate 
whether prevalence is associated with antibiotic resistance plasmids. It is hypothesised that 
the prevalence of ESBLs in this area is related to the conjugative resistance plasmids 
IncL/M, IncF, IncN and IncI1.   
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2.1 Materials and Methods  
2.1.1 Isolate Collection and Phenotypic Detection 
Bacterial isolates (n=236) of Enterobacteriaceae isolated from urinary tract infections were 
obtained from the Leicester Royal Infirmary hospital (Leicester, England). More 
description of isolate collection and storage can be found in 6.1 of Appendix. The Leicester 
Royal Infirmary was chosen as a collection site as a large number of samples are received 
from all over the Midlands, and the Midlands has a large population of a wide variety of 
ethnic groups. Informed consent from patients was not required, as waste material (bacterial 
cultures) was collected only, therefore there is no link to patient data. ESBL production was 
confirmed phenotypically via the MAST ESBL ID double disc synergy method, 
conforming to the European Committee on Antimicrobial Susceptibility (EUCAST) 
standards.  Discs contained Cefotaxime, Ceftazidime and Cefpodoxime with an ESBL 
inhibitor (clavulanic acid) counterpart. Plates were incubated for 18 hours at 37°C. A zone 
of inhibition difference of 5mm or more between the beta-lactam and the ESBL inhibitor 
clavulanic acid, indicated a positive result for ESBL production. Four control isolates were 
obtained from Public Health England: NCTC 13353 (CTX-M-15), NCTC 13351 (TEM-3), 
NCTC 13368 (SHV-18) and NCTC 13442 (OXA-48) for use as controls in phenotypic and 
genotypic tests (see table 6-1). 
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2.1.2 DNA extraction and Genotypic Detection by Multiplex PCR.   
The method used for DNA extraction has previously been outlined (Reid & Samarasinghe, 
2018). Genotypic identification was by means of a multiplex PCR method for the detection 
of the ESBL-producing genes (CTX-M, SHV, TEM and OXA). These were then further 
characterised into the CTX-M family (CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and 
CTX-M-25) by another multiplex PCR assay. The GoTaq G2 Flexi DNA Polymerase kit 
was chosen for all PCR assays (Promega, Southampton, UK). PCR amplification reactions 
were performed using the PikoReal® 96 well Real Time-PCR platform (ThermoFisher, 
Loughborough, UK) in a volume of 25μl containing 5μl of 5X Flexi Buffer, 2μl of 25 mM 
MgCl2,  0.5 μl of 10 mM  dNTPs, 0.125 μl of 5U/μl GoTaq G2 Flexi DNA polymerase, 400 
nM of each primer, 2.5μl of DNA template and made up to 25μl with water.  
Cycling parameters for the first multiplex assay were as follows: an initial denaturation at 
94°C for 5 min; followed by 35 cycles of 94°C for 30 s, annealing at 65°C for 1 min 
(gradual temperature decrements of 0.5°C per cycle, final annealing temperature 48°C), and 
72°C for 1 min; and with a final extension at 72°C for 10 min.  
Cycling parameter for the second multiplex assay were as follows: initial denaturation at 
94°C for 5 min; 30 cycles of 94°C for 25 s; 52°C for 40s and 72°C for 50 s; and a final 
extension at 72°C for 6 min. Primers can be found in table 2-1. More details of primer 
design can be found in 6.4.1. 
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Table 2-1 Primers used in this study.  Primers for the first multiplex PCR assay were TEM, SHV, CTX-M and OXA. The 
primers for the second multiplex PCR assay were CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25. Primers 
were designed using the OligoAnalyzer 3.1 (Integrated DNA Technologies Inc, Illinois, USA) Primers were then checked 
for specificity by the BLAST software (National Center for Biotechnology Information, Bethesda, USA). All PCR 
products were ran on a 2% agarose gel (UltraPure™ Agarose, ThermoFisher Scientific, Paisley, UK) for 90 mins at 60 
Volts. A GeneRuler 50 bp DNA Ladder, ready-to-use (ThermoFisher Scientific, Paisley, UK) was used for comparison. 
 
2.1.3 Multiplex PCR-based Replicon Typing 
Each isolate was sub-cultured in Luria Betani broth overnight at 37°C (recipe can be found 
in table 6-2 of Appendix). Plasmids were extracted using the Illustra PlasmidPrep Mini 
Spin Kit (GE Healthcare Life Sciences, Buckinghamshire, UK). More detail of the plasmid 
extraction method can be found in 6.3.2 of Appendix. Detection of plasmids was by means 
of adapting the replicon typing assay designed by (Carattoli, 2005). PCR amplifications 
Primer Forward Primer Reverse Primer Product 
Size 
Reference 
TEM-1 CGG ATG GCA TGA CAG TAA GAG AGG ACC ACT TCT GCG CTC G 782 (Reid & 
Samarasin
ghe, 2018) 
SHV-18 CTCAAGGATGTATTGTGGTTATGC CTA CGA GCC GGA TAA CGC G 914 (Reid & 
Samarasin
ghe, 2018) 
CTX-M CGTCATCTATGTTCGCCGAC GCATCTCAGTCGGATCGAGC 551 (Reid & 
Samarasin
ghe, 2018) 
OXA-48 CGGAATGCCTGCGGTAGCAAAG CAGCCCTAAACCATCCGATG 700 (Reid & 
Samarasin
ghe, 2018) 
CTX-M-1 AAA AAT CAC TGC GCC AGT TC AGC TTA TTC ATC GCC ACG TT 415 (Al-
Mayahie, 
2013) 
CTX-M-2 AGC TTA TTC ATC GCC ACG TT CCA GCG TCA GAT TTT TCA GG 552 (Al-
Mayahie, 
2013) 
CTX-M-8 TCG CGT TAA GCG GAT GAT GC CAA AGA GAG TGC AAC GGA TG 666 (Al-
Mayahie, 
2013) 
CTX-M-9 CAA AGA GAG TGC AAC GGA TG ATT GGA AAG CGT TCA TCA CC 205 (Al-
Mayahie, 
2013) 
CTX-M-25 GCA CGA TGA CAT TCG GG AAC CCA CGA TGT GGG TAG C 327 (Al-
Mayahie, 
2013) 
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were performed in a volume of 25ul containing 5 µl of 5X Flexi Buffer, 2 µl of 25 mM 
MgCl2, 0.5 µl of 10 mM dNTPs, 0.125 µl of 5U/μl GoTaq G2 Flexi DNA polymerase, 400 
nM of each primer and 2.5 µl of plasmid DNA. Cycling parameters were as follows: initial 
denaturation at 94°C for 5 min 30 cycles of denaturation at 94°C for 1 min, annealing at 
65°C for 30 sec, extension at 72°C for 30 sec and a final extension at 72°C for 5 min. 
Primers can be found below in table 2-2. More details of primer design can be found in 
6.4.1. 
Table 2-2 Primers used in multiplex replicon-typing.  Primers for IncFII, IncI1, IncFIA, IncN and IncL/M were designed 
using the OligoAnalyzer 3.1 (Integrated DNA Technologies Inc, Illinois, USA) Primers were then checked for specificity 
by the BLAST software (National Center for Biotechnology Information, Bethesda, USA). All PCR products were ran on 
a 2% agarose gel (UltraPure™ Agarose, ThermoFisher Scientific, Paisley, UK) for 90 mins at 60 Volts. A GeneRuler 50 
bp DNA Ladder, ready-to-use (ThermoFisher Scientific, Paisley, UK) was used for comparison. 
 
 
Primer Forward Primer Reverse Primer Product 
Size 
Reference 
IncFII TGTTTCCACTATGACCCGCT TGATACATCGAGGGCAGCAA 246 This study 
IncI1 CGGGAATGTCTGTTGTTGCA ATCGGCTTCATCCTGGTGAA 155 This study 
IncFIA CCA TGC TGG TTC TAG AGAAGGTG GTATATCCTTACTGGCTTCCGCAG 462 (Carattoli
, 2005) 
IncN GTCTAACGAGCTTACCGAAG GTTTCAACTCTGCCAAGTTC 559 (Carattoli
, 2005) 
IncL/M GGATGAAAACTATCAGCATCTGAAG CTGCAGGGGCGATTCTTTAGG 785 (Carattoli
, 2005) 
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2.1.4 Statistical Analysis 
The Chi Square test was used for statistical comparison and the Spearman Rank Correlation 
test was used to analyse the relationship between plasmids and ESBLs. P values < 0.05 
were regarded as significant. 
2.2 Results  
236 Enterobacteriaceae were tested by multiplex PCR for the ESBL genes CTX-M, TEM, 
SHV and OXA; and the CTX-M sub-groups CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 
and CTX-M-25. Multiplex PCR-based replicon typing tested for IncFII, IncFIA, IncL/M, 
IncN and IncI1. Results were ran on agarose gels and can be found in figure 5-VI and 5VII. 
The PCR assay assigned the four controls to their correct phylogenetic groups.  
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ESBL genes were identified as follows: CTX-M = 169 (71.6%) OXA = 18 (7.6%), TEM = 
9 (3.8%) and SHV = 9 (3.8%). Multiple resistance genes were detected in 16% of isolates, 
specifically CTX-M + OXA = 16 (6.8%), CTX-M + TEM = 12 (5.1%), CTX-M + OXA + 
SHV = 5 (2.1%) and CTX-M + SHV = 5 (2.1%). This can be seen in figure 2-I. A total of 
31 isolates did not contain any of the four genes tested. 
 
Figure 2-I Frequency of ESBL producing UTI isolates in the Leicestershire area. 236 isolates were tested for the presence 
of CTX-M, TEM, OXA and SHV genes by multiplex PCR analysis. All genes were detected; however, CTX-M was the 
most frequent.  
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CTX-M genes were identified as follows: CTX-M-1 = 148 (84.1%), CTX-M-9 = 22 
(12.5%), CTX-M-25 = 3 (1.7%), CTX-M-8 = 2 (1.1%) and CTX-M-2 = 1 (0.6%). This can 
be seen in figure 2-II. All isolates identified as containing CTX-M in the previous assay, 
contained at least one of the CTX-M sub-groups tested. One isolate contained both CTX-
M-1 and CTX-M-8. 
  
 
  
 
 
 
 
 
 
Figure 2-II Frequency of CTX-M sub-groups in UTI isolates in the Leicestershire area. 169 isolates previously identified 
as containing the CTX-M gene, were tested for the presence of CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-
25 genes by multiplex PCR analysis. All genes were detected, however CTX-M-1 was the most frequent. A combination 
of CTX-M-1 and CTX-M-8 was found.  
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Plasmids identified were as follows: IncL/M was detected in 69 (29.2%) of isolates, IncFII 
was detected in 65 (27.5%) of isolates, IncN was detected in 34 (14.4%) of isolates, IncFIA 
was detected in 55 (23.3%) of isolates and IncI1 was detected in 12 (5.1%) of isolates. This 
can be found in figure 2-III. 235 of the 236 isolates contained at least one plasmid. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-III Frequency of replicon types in ESBL producing UTI isolates in the Leicestershire area. 236 isolates were 
tested for the presence of IncL/M, IncN, IncI1, IncFII and IncFIA genes by multiplex replicon-typing PCR analysis. All 
genes were detected; however, IncL/M was the most frequent, followed closely by IncFII. 
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Multiple plasmids were found in 37% of isolates. IncL/M, IncFII + IncFIA was detected in 
23 (9.8%) isolates. IncN + IncFII was detected in 13 (5.5%) isolates. IncL/M + IncN was 
detected in 12 (5.1%) isolates. IncFII + IncFIA was detected in 12 (5.1%) isolates. IncL/M 
+ IncFIA was detected in 11 (4.7%) isolates. IncL/M, IncI1 + IncFIA was detected in 3 
(1.3%) isolates IncL/M, IncN and IncFII was detected in 3 (1.3%) isolates. IncI1 and IncFII 
was detected in 3 (1.3%) isolates. IncN, IncI1, IncFII + IncFIA was detected in 2 (0.9%) 
isolates. IncL/M + IncFII was detected in 2 (0.9%) isolates. IncL/M + IncI1 was detected in 
1 (0.4%) isolate. IncN, IncI1 + IncFII was detected in 1 (0.4%) isolate. IncI1 + IncFIA was 
detected in 1 (0.4%) isolate. This can be found in figure 2-IV. 
 
Figure 2-IV Frequency of dual, triple and quadruple plasmids in ESBL producing UTI isolates in the Leicestershire area. 
236 isolates were tested for the presence of IncL/M, IncN, IncI1, IncFII and IncFIA genes by multiplex PCR analysis. All 
genes were detected; however, CTX-M was the most frequent. 
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A spearman rank was carried out to access the correlation between ESBL genes and 
plasmid type. A significant positive correlation between the CTX-M gene and IncL/M, N, 
FII and FIA plasmids was found. Also found was a significant positive correlation between 
the IncFII plasmid and the CTX-M-8 gene. No significant correlation was found for the 
TEM, SHV and OXA genes and any of the plasmids. None of the other CTX-M sub-types 
had a significant correlation with any of the plasmids. 
2.3 Discussion 
The major cause of antibiotic resistance in Enterobacteriaceae is ESBL-production. ESBL-
producing UTIs are a major problem in the UK, due to their increasing prevalence and 
limited treatment options (Harwalkar, 2013). Given how common ESBL-producing 
infections are worldwide, prevalence studies are important to ascertain where resistance is a 
major problem. 
In this paper, the prevalence of ESBL genes was investigated in UTIs in the Leicestershire 
area of the UK. In short, the CTX-M gene was found in 71.6% of samples, in comparison 
genes TEM, SHV and OXA were detected in ≤16% of samples. The most prevalent CTX-M 
was CTX-M-1 at 84.1%. The most common plasmid found was IncL/M at 29.2%, with 
IncFII following closely at 27.5%. Multiple plasmids were found in 37% of isolates, with 
the IncL/M, IncFII and IncFIA combination the most common. A significant correlation 
between CTX-M and all plasmids except IncI1 was found, however no other gene family 
significantly correlated with any of the plasmids.   
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Here, the relevance of findings of this study in relation to other studies will be evaluated 
within the context of the One Health Approach. The One Health Approach describes a 
holistic and multisectoral approach to antimicrobial resistance, as resistant organisms exist 
in humans, animals, food and the environment (Goutard, et al., 2017). The main aim of the 
One Health Approach is to ensure that antimicrobial agents continue to be effective by 
developing policies that promote the responsible use of antimicrobial agents. The 
development of policy decisions depends on economic and scientific evidence. Prevalence 
studies are an important part of this (Aidara-Kane, et al., 2016).   
This is the first study to investigate the prevalence of ESBL-producing Enterobacteriaceae 
and their relationship to plasmids, in the Leicestershire area of the UK.  
In this study, it has been found that CTX-M was the most common ESBL and the most 
common sub-group was CTX-M-1. This is comparable with other European countries, and 
is consistent with the worldwide dissemination of the CTX-M ESBL (Shaikh, et al., 2015; 
Canton, 2012; Celik, 2010; McNulty, et al., 2018). CTX-M-1 has been found to be the most 
prevalent gene in humans, animals and food in the UK, frequently found in poultry and 
cattle isolates (Day, et al., 2016).  It has been established that the prevalence of ESBLs 
differs significantly between countries. Within Europe, a high prevalence has been seen in 
Southern Europe, while a generally lower prevalence is seen in Northern Europe. Outside 
of Europe, Turkey and India have reported high levels of ESBLs (Bevan, et al., 2017).  
The high number of CTX-M isolates found in this area may be due to the multicultural 
nature of the Leicestershire community. A study in a hospital in Birmingham, UK also 
found a high level of ESBL and suggested that this could be due to a high immigrant 
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population (Wragg, et al., 2017).  One possible cause of elevated levels of ESBLs in high 
immigrant populations could be faecal colonisation. Transmission of faeces to the urinary 
tract is frequently a cause of UTI. As E.coli is a common inhabitant of the gastrointestinal 
tract, it is possible that CTX-M-producing E.coli could be a commensal bacteria that can 
become pathogenic upon colonization of the urinary tract (Bien, et al., 2012). To further 
this, a direct link between conjugative resistance plasmids in the microflora and increased 
treatment failure has been found (Kamruzzaman, et al., 2017). In another study in 
Birmingham, they found a direct link between place of birth and CTX-M-1 colonisation in 
stool samples. Those that were originally born in Afghanistan saw the highest colonisation 
at 60%, followed by those born on the Indian subcontinent (India, Pakistan, Bangladesh or 
Sri Lanka) with a 25% colonisation. Those that travel to certain areas were also associated 
with CTX-M colonisation. Travellers to South Asia (India, Pakistan, Bangladesh, Sri Lanka 
or Nepal) in the last year had a 38.5% colonisation, suggesting a geographical, rather than 
ethnic susceptibility (McNulty, et al., 2018).  
In India, a prevalence rate of 53% for CTX-M was seen in a study detecting ESBLs in 
UTIs. Antibiotic usage in India is far higher than in the UK, due to issues with lack of 
restriction in antibiotic prescribing which could explain why they saw a higher incidence of 
CTX-M (Rath, 2011). 
Prevalence rates of CTX-M have been seen as high as 94.4% in Iran, 73% in Mexico, 
98.7% in Japan and 100% in Ghana (McNulty, et al., 2018). These studies show that the 
problem of ESBL producing infections is not limited to the UK. As bacteria do not 
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recognise geographical borders, so too does the approach to tackling AMR need to be 
borderless.  
This study found that 16% of isolates contained more than one ESBL type. Interestingly, in 
all of the multi-ESBL isolates CTX-M was always present, this suggests that CTX-M may 
play a key role in the production of MDR bacteria. Of these, CTX-M and OXA were the 
most common multi-ESBL, detected in 16 isolates. 2% of isolates contained three genes, 
specifically, CTX-M, OXA and TEM. It has been reported that CTX-M-15 combined with 
an OXA-30 gene can survive β-lactamase inhibitors, since OXA-30 is poorly inhibited and 
also confers resistance to cefepime (Agyekum, et al., 2016). Although this study did not 
specifically type the ESBL genes in these isolates, it is possible that it could be this 
combination present. The coexistence of CTX-M and other antibiotic resistance genes 
could be one of the reasons why CTX-M has been so successful. This has been found 
elsewhere, with incidences of combinations of ESBLs as high as 95.4%, with regards to the 
CTX-M and SHV combination (Barrios, et al., 2017; Moghanni, et al., 2018). The 
combination of three genes found in this study has also been found elsewhere (Moghanni, 
et al., 2018). Furthermore, other Multi ESBL combinations have also been found in animals 
and the environment, suggesting that multiple ESBL combinations are not limited to 
humans. This data combined shows that multi ESBLs are widespread and could pose a 
significant threat (Qiao, et al., 2017; Zarfel, et al., 2013).  
A similar incidence of ESBLs have been reported in livestock and companion animals 
globally (Qiao, et al., 2017; Tippelskirch, et al., 2018; Schill, et al., 2017; Melo, et al., 
2018; Zogg, et al., 2018).  In a study looking at canine UPEC in Switzerland, CTX-M-1 
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was found in 28.6% of ESBL-producers suggesting that dogs, a common companion 
animal worldwide, may be a reservoir for CTX-M-1 spread into humans (Zogg, et al., 
2018). In addition to this, blaCTX-M-14 IncK pCT plasmids, previously only found in 
cattle in the UK, have been detected in turkey and human isolates. This suggests a possible 
dissemination of CTX-M genes amongst other animals and humans. (Stokes, et al., 2012). 
Both livestock and companion animals could be considered a major vector of ESBL-
producing bacteria (Day, et al., 2016). With raw meat a speciality in some countries and the 
rise of raw food diets in both humans and companion animals, a high level of ESBLs in 
livestock is a cause for concern. As it has been suggested that the majority of ESBL 
infections are community-acquired, this could suggest a relationship between companion 
animals, livestock and humans. 
This study focused on the prevalence of IncL/M, IncFII, IncI1, IncFIA and IncN. These 
conjugative plasmids have previously been associated with the dissemination of antibiotic 
resistance determinants such as ESBLs, in Enterobacteriaceae and other bacteria. 
Whilst IncL/M was the most common plasmid found in the isolates tested, when IncFII and 
IncFIA (both members of the IncF group) are combined, the frequency is far higher at 
50.8%.  The IncF group is one of the most common plasmids found in UTI isolates and is 
frequently associated with CTX-M (Agyekum, et al., 2016). Studies show that IncL/M is 
also highly common, and both have been termed an “epidemic” plasmid (Carattoli, 2011). 
Both of these plasmids can persist for months without the need for selective pressure by 
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antibiotic usage (Kamruzzaman, et al., 2017). This suggests that simply reducing antibiotics 
by antibiotic stewardship alone will not reduce the prevalence of these plasmids.  
The distribution of plasmids harbouring ESBL genes in this population differs from the 
distribution described in other studies. Studies have agreed that CTX-M is associated with 
IncN, IncFII and IncL/M, however reports have shown that CTX-M is also associated with 
IncI1. IncI1 plasmids harbouring CTX-M have been described in the UK, US, Belgium, 
Netherlands, France and Australia in isolates from horse, cattle and human isolates 
(Zurfluh, et al., 2015). Studies have also found that other ESBL types are associated with 
particular plasmids. It has been found that SHV can be associated with IncFII, IncL/M and 
IncI1. Likewise, TEM can be associated with the same plasmids, and additionally IncI1 
(Carattoli, 2009). A reason for the differing results could be due to different antibiotic and 
environmental selection pressures in this population, leading to selection of CTX-M 
harbouring IncL/M, IncF, and IncN plasmids, but not IncI1 plasmids.  
In this study, no significant correlation between CTX-M-1 (the most common CTX-M 
subtype) and any other plasmid was found. There are conflicting reports within the 
literature with regards to the most significant association between CTX-M-1 and plasmid 
types. Some reports suggest a correlation between CTX-M-1 and IncFII, whilst others, 
mainly in Europe, suggest a correlation between CTX-M-1 and IncI1. Other reports suggest 
no overall correlation at all (Madec, et al., 2015; Day, et al., 2016).  It appears that the 
association between CTX-M-1 and plasmids differs between geographical locations and 
sample type. These differences in reports could be attributed to socioeconomic factors, 
 83 
animals and number of samples. It could be suggested that CTX-M-1 is equally adapted to 
most plasmid types, therefore a significant correlation between just one plasmid was not 
seen. It could also be suggested that the high level of CTX-M-1 in this population is also 
due to another mechanism other than conjugative plasmids, such as chromosomally 
mediated resistance. 
A significant correlation between CTX-M-8 and IncFII was found. Whilst CTX-M-8 is not 
the highest prevailing gene found in this study, it is a significant finding, as IncFII was very 
common. A link has been found between CTX-M-8 harbouring IncI1 plasmids and 
companion animals. This could further strengthen the argument that CTX-M genes could be 
passed, via plasmids, from companion animals to humans (Melo, et al., 2018). 
Though studies suggest that IncN does not contribute to the prevalence of CTX-M  in 
humans to the same extent as incI1, this was not the case in this study, as IncN was seen to 
be more prevalent than IncI1 and a significant correlation was found (Zurfluh, et al., 2014). 
This theory has also been contradicted by another study, that found that IncN was in fact 
associated with humans and 95.5% of isolates containing IncN harboured CTX-M-1 (Day, 
et al., 2016). In a Danish study, IncN plasmids carrying CTX-M-1 were seen in both pigs 
and farm workers, and it was demonstrated that these plasmids were transmitted within the 
farm, showing animal to human transmission of these plasmids harbouring CTX-M 
(Carattoli, 2011). 
Multi-replicon plasmids were found in 37% of isolates. Multiple plasmids frequently occur 
in the same bacterial cell, however, cross-interference between plasmid replicons 
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guarantees that the most closely related plasmids are incompatible and cannot stably persist 
together (Kamruzzaman, et al., 2017). When multi-replicon plasmids occur, generally one 
replicon is usually highly conserved, and the other is free to diverge. This gives the 
bacterial host the benefit of being able to change antibiotic resistance determinants and 
virulence factors, depending on antibiotic pressure and environment (Zurfluh, et al., 2015). 
Multi-replicons have been found in other UTI isolates, and multi-replicons containing 
multiple IncF types appear to be common (Agyekum, et al., 2016). Multi replicons are also 
common in the environment. A study found that the diversity of plasmids found in the 
environment was higher than in UTIs in the same area. CTX-M-1’s in the environment 
have been shown to be associated with IncI1 and IncN (Zarfel, et al., 2013). A report has 
suggested a direct link between wastewater treatment plants and ESBL-producing UTIs.  
Sewage sludge used for agriculture may be one of the ways that ESBL-producing isolates 
enter the food chain (Zarfel, et al., 2013). It has been established that CTX-M-1 producing 
E.coli in manure spread on fields can survive in the soil for at least a year. This 
demonstrates the capability of antibiotic resistant bacteria to survive under environmental 
conditions in the absence of antibiotic selection pressure (Zurfluh, et al., 2014). 
A limitation of this study is that isolates were not categorised into source of isolate 
(community/hospital acquired). However, other studies suggest that the CTX-M family and 
ESBLs in general are associated with community-acquired infection (Hayakawa, et al., 
2017; Qiao, et al., 2017). In this study, only ESBL-positive isolates were collected. From 
this, the level of ESBL resistance as a whole cannot be determined. This study should be 
followed up regularly, to study the trends of antibiotic resistance in this area. More 
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surveillance studies on animal and environmental isolates are needed, to fully understand 
the relationship between these and human infections.  
In this study, similar results to what has been found in the rest of the UK and worldwide 
have been found. CTX-M-producing Enterobacteriaceae is a major threat to patient care 
and healthcare costs. Genotypic prevalence studies are an important contribution to the 
understanding and prediction of antibiotic resistance evolution and antibiotic stewardship. 
Knowledge of plasmid types circulating in bacterial populations is vital to advancing a new 
prospective to control these plasmids, such as replicon-targeting compounds. A strategy to 
prevent the further dissemination of these plasmids needs to be implemented.  
Combined, these findings highlight the importance of restricting antibiotics sales to only 
those with medical prescriptions and appropriate use, as many low and middle-income 
countries have not yet enforced policies that prevent widespread self-medication with 
antibiotics. 
This study reinforces the One Health approach and underpins the importance of antibiotic 
stewardship and infection prevention schemes in humans, animals, food production and the 
environment in order to limit the spread of ESBL-producing Enterobacteriaceae, not only 
in the UK, but worldwide.  
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Abstract 
Background 
Overuse of beta-lactam antibiotics has led to selection for extended-spectrum β-lactamase 
(ESBL) producing Enterobacteriaceae, a major cause of antibiotic resistant urinary tract 
infections (UTIs). Standard detection methods are time-consuming, with disputed accuracy.   
This study describes a novel real-time PCR method to detect CTX-M, SHV, OXA and 
TEM.  
Methods 
A total of 181 Enterobacteriaceae isolates from UTIs were collected from the Leicester 
Royal Infirmary, UK. A multiplex Plexor®-based real-time PCR assay detected ESBLs 
using their specific amplicon melting temperature, during each cycle, removing the need for 
a melt-curve analysis. Validation was achieved by end-point PCR and disk diffusion.  
Results 
The method was able to produce rapid and accurate results, achieving a sensitivity and 
specificity of 94.9% and 72% respectively, and the assay can differentiate between the 
different ESBL genes, with ease. 
Conclusions 
With further investigation, a Plexor®-based assay could form the basis of a high-
throughput kit that health services could use to detect ESBLs or other antibiotic resistance 
genes.  
Keywords: Extended-spectrum beta-lactamases, urinary tract infections, Real-Time PCR, 
rapid diagnostics, antibiotic resistance. 
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3 Introduction 
Antibiotic resistance is a natural process, whereby bacteria exchange genes via horizontal 
transfer, however the overuse of antibiotics has caused a permanent selective force for 
resistance mechanisms (Canton, et al., 2012).  In the O’Neill report in 2016, it was 
estimated that every year at least 700,000 people die as a result of antibiotic resistant 
infections (O'Neill, 2016). 
Extended-spectrum β-lactamases (ESBLs) are one of the most common types of antibiotic 
resistance found in Enterobacteriaceae and are a major public health concern, both in 
hospital settings and in the community (Fournier, et al., 2013; Esteve-Palau, et al., 2015). 
First discovered in the 1980’s, ESBLs have since increased massively, becoming a major 
public concern (Canton, et al., 2012). 
ESBLs are able to hydrolyze extended – spectrum cephalosporins (cefotaxime, ceftriaxone, 
ceftazidime and cefepime) and monobactams (aztreonam) (Esteve-Palau, et al., 2015) 
(Roschanski, et al., 2014). The most common families of ESBLs found are CTX-M, SHV, 
OXA and TEM (Canton, et al., 2012).   
Urinary tract infections (UTIs) are the most common infection found in humans (Yang, et 
al., 2010). The majority of both community-acquired and nosocomial UTIs are caused by 
uropathogenic Escherichia coli (UPEC) strains (Yang, et al., 2010). Serious infection by 
ESBL-producing UPEC can be linked to increased length of hospital stay, admittance to an 
intensive care unit, catheterization, increased mortality, morbidity and healthcare cost 
(Birkett, et al., 2007) (Esteve-Palau, et al., 2015) (Shin & Ko, 2015) (Wintermans, et al., 
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2013). Therefore, early detection would benefit both the patient and the health care 
provider. Screening for ESBL-producing uropathogens is commonly achieved by means of 
selective agar plates, such as the commercially available ESBL agar. Isolates are also tested 
for antibiotic sensitivity by disk diffusion or broth microdilution (Roschanski, et al., 2014). 
These procedures can take 4-6 days to obtain an antibiotic resistance profile after the 
culture, isolation and characterization of pathogens from a patient sample.  
In the O’Neill report, it was suggested that rapid diagnosis could change the way antibiotics 
are used. Reducing the time spent on broad-spectrum antibiotics by prescribing a more 
appropriate treatment, increases the favorability of the outcome of the patient and shortens 
the stay in hospital. Rapid detection of ESBL isolates also has other benefits, including 
infection control and prevention of outbreaks through the use of hospital hygiene 
precaution measures (Birkett, et al., 2007) (Lupo, et al., 2013) (Swayne, et al., 2013). 
Therefore, rapid and sensitive detection of infections thought to be of the ESBL type is of 
the utmost importance for patient outcome, the economy and outbreak control.  
In this study, a multiplex real-time assay was developed and validated to detect the most 
prevalent ESBL-producing genes in bacterial isolates found in UTIs, based on the amplicon 
melting temperature.  
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3.1 Methods 
3.1.1 Bacterial Isolates and DNA Extraction 
Bacterial isolates (n=181) of Enterobacteriaceae isolated from urinary tract infections were 
obtained from the Leicester Royal Infirmary hospital (Leicester, England). More 
description of isolate collection and storage can be found in 6.1 of Appendix. The Leicester 
Royal Infirmary was chosen as a collection site as a large number of samples are received 
from all over the Midlands, giving a wide population base. A total of 25 of the samples 
were non β-lactamase producing strains of Enterobacteriaceae, and 156 were β-lactamase 
producing strains. The presence or absence of ESBL production was previously identified 
by disk diffusion. Waste material (agar plates) was collected and therefore informed 
consent from patients was not required. Both catheter and non-catheter patients, 
symptomatic and non-symptomatic patients were included. Four control isolates were 
incorporated: NCTC 13353 (CTX-M-15), NCTC 13351 (TEM-3), NCTC 13368 (SHV-18) 
and NCTC 13442 (OXA-48), obtained from Public Health England (see table 6-1 in 
Appendix). Each isolate was sub-cultured on Müller-Hinton agar plates for 24 hr. at 37°C 
(recipe can be found in table 6-2 of Appendix). 2-3 colonies were picked and suspended in 
50 µl sterile distilled water and then heated in a AccuBlock dry bath (Labnet International 
Inc, Windsor, Berkshire) for 10 min at 94°C.  
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3.1.2 Primers   
Table 3-1 Primers used in this study 
 
The allelic variants that these primers can detect have been previously shown and can 
detect 149 variants of ESBLs (Singh, et al., 2016). These variants include CTX-M-1, CTX-
M-15 and CTX-M-9 that have been shown to be highly prevalent in UTIs in the UK 
(Canton, et al., 2012). These can be found in table 3-1. More details of primer design can be 
found in 6.4.2. 
 
3.1.3 Qualitative Real-Time PCR  
The Plexor® qPCR (Promega, Southampton, UK) mastermix kit was used for its suitability 
in multiplex real-time PCR and its previous use in diagnostic assays. The Plexor® qPCR 
system mechanism has been previously described (Promega Corporation, 2009). In typical 
real-time PCR assays, the accumulation of a product is accompanied by an increase in 
Oligo Forward Reverse Product 
Size 
Reference 
OXA48 AGCAAAGGAATGGCAAGAAA CGCCCTGTGATTTATGTTCA 65 (Singh, et 
al., 2016) 
SHV GGTCAGCGAAAAACAYCTTG GCCTCATTCAGTTCCGTTTC 195 (Singh, et 
al., 2016) 
TEM GATACGGGAGGGCTTACCAT GGATGGAGGCGGATAAAGTT 146 (Singh, et 
al., 2016) 
CTX-M AATCTGACGCTGGGTAAAG 
 
CCGCTGCCGGTTTTATC 304 (Singh, et 
al., 2016) 
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fluorescence. However, the Plexor® qPCR system differs in that the accumulation of a 
product leads to a decrease in fluorescence. Primers are easy to design, and less expensive 
than using probes. Primer design requires the addition of an iso-dC label adjacent to a 
fluorescent reporter on one strand. The Plexor® mastermix contains a dabcyl-iso-dGTP 
label as a quencher. This can be seen in figure 3-I. Plexor® primers are less expensive than 
probes and have a higher specificity than SYBR green chemistry (Promega Corporation, 
2009).   
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Figure 3-I The Plexor® qPCR system and the method of detection used in this study. The Plexor® qPCR system requires a florescent 
reporter, adjacent to an iso-dC label, to be attached to one of the primers in each pair. Florescence is then quenched by incorporation of a 
Dabcyl-iso-dGTP label contained in the mastermix, when bound to another DNA strand during the extension phase of the PCR cycle. 
Therefore, as product increases, florescence decreases. When the amplicon melts, the strands dissociate and the quencher is released. 
Shorter amplicons melt at lower temperatures to longer ones, allowing differentiation between the products. 
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Qualitative real-time PCR conditions such as annealing temperature and primer 
concentration were optimised in simplex, and once satisfied, in multiplex. The amplicons of 
the control isolates were initially tested using high resolution melting curve analysis, first in 
simplex and then multiplex to determine the melting point of the amplicon. An increase in 
temperature increments between 84°C and 86°C was implemented to aid resolution 
between the amplicon melting points of CTX-M and TEM. See 6.6 of Appendix for more 
details on optimization of the assay. An agarose gel image of the results of the optimization 
stage can be found in figure 6-X.  
Assays were performed in 12.5 µl reactions consisting of 6.25 µl of 2X Plexor® Master 
Mix, 0.5 µl of each primer mix, (forward and reverse primer combined) at a final 
concentration of 200 nM and 2.5 µl template DNA. The five previously mentioned controls 
were included in the assay, along with a no template control (NTC).  
The qualitative real-time PCR amplification protocol was performed in a PikoReal® 96 
well Real Time-PCR platform (ThermoFisher, Loughborough, UK). The qualitative real-
time PCR amplification program comprised of the following steps: initial denaturation for 
10 min at 95 °C, and then 40 cycles of 95 °C for 10 s, annealing at 70°C for 40 s (gradual 
temperature decrements of 0.2°C per cycle, final annealing temperature 60°C), and 
fluorescence readings were taken from cycle 16 onwards at 72°C, 76°C , 78°C, 84°C, 
84.2°C, 84.4°C, 84.6°C, 84.8°C, 85°C, 85.2°C, 85.4°C, 85.6°C, 85.8°C, 86°C, 88°C and 
90°C for 10 s each.  
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3.1.4 Limit of Detection 
For each of the ESBL types, the limit of detection was determined in triplicate with five 
1:10 dilutions using DNA extracted by the method mentioned previously. DNA 
concentration was measured using a Qubit 3 fluorometer for the highest DNA 
concentration, and then concentrations were estimated by calculation from then on.  
3.1.5 Validation 
ESBL production was confirmed phenotypically via the MAST ID double disc synergy 
method outlined by the European Committee on Antimicrobial Susceptibility (EUCAST) 
Discs contained Cefotaxime, Ceftazidime and Cefpodoxime with their clavulanic acid 
counterpart. Plates were incubated for 18 hours at 37°C. A zone of inhibition difference of 
5mm or more indicated a positive result for ESBL production.  
A multiplex end-point PCR assay was used as a reference for validation. PCR amplification 
reactions were performed in a volume of 25μl 5 µl of 5X Flexi Buffer, 2 µl of 25 mM 
MgCl2, 0.5 µl of 10 mM dNTPs, 0.125 µl of 5U/μl GoTaq G2 Flexi DNA polymerase ,400 
nM concentrations of each primer, and 2.5μl of DNA template. Cycling parameters for the 
multiplex assay were as follows: an initial denaturation at 94°C for 5 min; followed by 35 
cycles of 94°C for 30 s, annealing at 65°C for 1 min (gradual temperature decrements of 
0.5°C per cycle, final annealing temperature 48°C), and 72°C for 1 min; and with a final 
extension at 72°C for 10 min. Primers can be found in table 3-2. 
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Table 3-2. Primers used in the validation end-point PCR assay 
 
 
3.1.6 Statistical Analysis 
The sensitivity, specificity, positive likelihood ratio and negative likelihood ratio was 
calculated using SPSS version 22. 95% confidence intervals for the sensitivity and 
specificity were calculated using exact Clopper-Pearson confidence intervals (Newcombe, 
1998). Whereas the Log method was used to calculate 95% confidence intervals for the 
likelihood ratios (Altman, et al., 2000). 
3.2 Results  
A Plexor®-based multiplex real-time PCR assay was designed to simultaneously detect the 
ESBL genes CTX-M, TEM, OXA and SHV, using amplicon melting temperatures, without 
the use of melting curve analysis. Figure 3-II shows the results of the development of the 
real-time PCR method. 
A total of 179 samples were collected from the Leicester Royal Infirmary and tested by 
qualitative real-time PCR.  The result of the multiplex assay was mostly in agreement with 
the results of the multiplex end-point PCR. The assay correctly identified 91.7% isolates 
tested. A summary of the statistical results can be found in Table 3. It is typical for a new 
Primer Forward Primer Reverse Primer Product 
Size 
References 
TEM-1 CGGATGGCATGACAGTAAGAG AGGACCACTTCTGCGCTCG 782 Own study 
SHV-18 CTCAAGGATGTATTGTGGTTATGC CTACGAGCCGGATAACGCG 914 Own study 
CTX-M CGTCATCTATGTTCGCCGAC GCATCTCAGTCGGATCGAGC 551 Own study 
OXA-48 CGGAATGCCTGCGGTAGCAAAG CAGCCCTAAACCATCCGATG 700 Own study 
. 
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diagnostic to be compared to a gold standard in order to determine if the new method 
diagnoses patients correctly. End-point PCR was used as the gold standard for comparison 
against the new diagnostic method. Seven very major errors/discrepancies and seven major 
errors/discrepancies were identified. Very major errors were defined as samples that 
showed as negative for ESBL genes by the qualitative real-time PCR assay, but positive by 
end-point PCR. These would be patients that may not be given treatment with the new 
method, which may have needed it. Major errors were defined as samples that showed as 
positive for ESBL genes by the qualitative real-time PCR assay, but negative by end-point 
PCR. These would be patients that would be given treatment with the new method, which 
may have not needed it.  
Interestingly, the real-time PCR assay picked up additional TEM genes in two of the 
isolates, which the end-point PCR had failed to. The NTC was assigned correctly as 
predicted.  
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Figure 3-II Data showing the change in florescence at cycles 16-31 (when florescence was detected) at low temperatures and at the 
melting point of each amplicon Data was normalized to the highest relative florescent unit (RFU). At temperatures below the Tm, 
florescence deceases as product increases each cycle. This is due to the incorporation of the Dabcyl-iso-dGTP quencher contained 
within the mastermix. At higher temperatures, florescence is very low as the majority of florescent reporters have been quenched. 
This change in florescence occurs at different temperatures for each amplicon, therefore the different products can be distinguished 
based on temperature. 
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In comparison, the disk diffusion method correctly identified ESBL production in 87.36% 
of tested isolates. Whilst the sensitivity was slightly higher than the qualitative real-time 
PCR, the specificity was significantly lower (see Table 3). Eighteen very major errors and 
five major errors were identified. The results of the statistical analysis can be found in table 
3-3. 
Table 3-3. Summary of statistical analysis. 
 Qualitative Real-Time PCR Disk Diffusion 
Accuracy  91.71% (86.70-95.29) 87.36% (81.64 – 91.82) 
Sensitivity  94.87% (90.15-99.97) 96.82% (92.72 – 98.96) 
Specificity  72% (50.61-87.93) 28.00% (12.07 – 49.39) 
Positive likelihood ratio 3.39 (1.81-6.36) 1.34 (1.05 – 1.72) 
Negative likelihood ratio 0.07 (0.03-0.15) 0.11 (0.04 – 0.33) 
 
3.2.1 Limit of Detection 
Measurement of DNA concentration and calculations are described in the methods. The 
limit of detection for each of the set of primers CTX-M, TEM, OXA and SHV was 
0.0004125ng/µl, 0.0242ng/µl, 0.000404ng/µl, and 0.000362 respectively. As TEM was not 
detected below 0.0242ng/µl, it is recommended that at least this amount of DNA is 
included in the test.   
3.3 Discussion  
Although other methods have been described for the detection of ESBLs, this is the first 
study to accurately and rapidly describe a multiplex real-time PCR assay to detect ESBLs, 
based on amplicon melting temperatures, without the need for a high-resolution melting 
curve analysis. Whilst there are other chemistries applied in real-time PCR that do not 
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require high-resolution melt-curve analysis for detection, such as Taqman, these tend to be 
far more expensive and require a higher level of user experience (Promega Corporation, 
2009). In this assay, the detection of products is based upon the melting temperature of 
amplicons, within each cycle. In the present study, 179 samples previously identified as 
ESBL-producers by disk diffusion methods, were tested using a Plexor®-based multiplex 
real-time PCR assay for the detection of 149 variants of the CTX-M, TEM, OXA and SHV 
genes in one amplification. The assay was able to correctly detect genes in 91.7% of the 
isolates in under 3 hours. In comparison, disk diffusion methods were able to correctly 
detect ESBL production in 87.4% of isolates. Whilst in this study, the disk diffusion method 
showed a slightly higher sensitivity than the qualitative real-time PCR method, this has not 
been seen in other studies (Yazdi, et al., 2012) (Tofteland, et al., 2006). It has also been 
reported that clinical failures may occur, even when an isolate is negative phenotypically 
(Gheldre, et al., 2003). This may have been seen in this study, as there were eighteen cases 
where ESBL genes were detected by end-point PCR, but the isolate was negative 
phenotypically. This further advocates the use of genotypic detection.  
ESBL-producing Enterobacteriaceae are a global growing concern, especially when it 
comes to UTIs. Current susceptibility testing requires at least 24 hr.; therefore, it is 
common practice to treat with empirical antibiotic therapy, without full pathogen 
information. Treating in this way can lead to ineffective therapy, causing an increase in 
clinical symptoms, including the possibility of urosepsis and ascending infection. It is well 
known that empirical treatment with antibiotics increases the population of resistant 
pathogens (Van der Zee, et al., 2016). Therefore, it is crucial that reliable, accurate and 
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rapid detection methods of antibiotic resistance are available. In addition, prevalence 
studies are highly important for monitoring the spread and evolution of antibiotic resistance 
genes.  
Not only can the assay detect ESBL production in isolates in under 3 hours, it can also 
differentiate between the major classes of ESBL, aiding in surveillance studies. In addition, 
this assay did not require any laborious primer modifications and the results are easy to 
interpret, with no further analysis required. The results from this assay could lead to 
treatment escalation much more quickly than current methods. However, due to the low 
number of negative samples tested in this study, it is difficult to determine if treatment de-
escalation could be concluded from the results of this assay. Nevertheless, due to the 
increased expense of PCR-based methods compared to current susceptibility testing 
methods, it is likely that only those patients who are suspected of having an ESBL 
producing UTI, such as patients who suffer from recurrent UTIs or those that are at higher 
risk (pregnant women, children, immunocompromised) would be tested. Therefore, the 
patient population tested in this study, represents the samples that would most likely be 
tested in practice. Until the negative likelihood ratio of this test can be more reliably 
proven, it is suggested that this test be used as an add-on to current testing in any patients 
that do not fall into the above criteria.  
In the future, more targets could be added to this multiplex assay, as long as they have a 
different amplicon melting temperature. This is achieved through primer design, as 
amplicon melting temperature is related to length and the ratio of CG/AT content. As 
technology improves, the melting temperature difference required between amplicons can 
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decrease, further increasing the number of targets possible in the assay. This study 
recommends that primers for other Carbapenamases and ampCs (other major antibiotic 
resistance genes) are added, to give this assay full breadth across the antibiotic resistance 
spectrum seen in UTIs.  
A multiplex Plexor®-based real-time PCR assay could provide a rapid, more sensitive, easy 
to interpret detection method, thereby helping to prevent the inappropriate use of 
antibiotics. It was found that this method could aid antibiotic susceptibility testing, if ESBL 
production is suspected. With further investigation this assay could form the basis of a high 
throughput kit that health services could use to detect ESBLS or other antibiotic resistance 
genes.  
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Abstract 
Background 
Urinary tract infections (UTIs) are one of the most common infections found in humans, 
with uropathogenic Escherichia coli (UPEC) the most common cause. It is thought that the 
main reason why UPEC is so successful, is its expression of a wide range of virulence 
factors including adhesins, capsules, toxins and iron-acquisition systems. The American 
cranberry Vaccinium macrocarpon produces proanthocyanins (PACs) which are tannins or 
stable polyphenols, and are reported to confer protection against bacterial infection. 
Cysticlean® capsules contain 240 mg of PACs and have been shown to produce a 
significant inhibition of E. coli adherence, in vitro and ex vivo, to uroepithelial cells. In this 
study, the Cephalosporin resistant E.coli isolate NCTC 1553 was analysed by qRT-PCR for 
the expression of virulence factors, before and after treatment with the cranberry product 
Cysticlean®. 
Methods 
RNA lysate was extracted using the Cells-to-CT™ 1-Step TaqMan™ Kit (ThermoFisher 
Scientific, Loughborough, UK) and qRT-PCR was carried out to detect the toxins SAT, and 
USP, the iron acquisition system ChuA, the protectins SoxS, KPSM, TraT and RecA, the 
antibiotic resistance gene CTX-M (encoding beta-lactamase production) and the 
transporters, IdfB and HcaT. 
Results 
The results showed that Cysticlean® significantly reduces the expression of the ten genes 
tested responsible for virulence and antibiotic resistance. This will eventually weaken 
 110 
bacterial coordination, decrease their survival abilities, and interfere with their virulence 
and antibiotic resistance mechanisms.  
Conclusion 
These results suggest that cranberry could be a suitable alternative to antibiotic prophylaxis 
for the prevention of recurrent UTI.  
 
Keywords:  urinary tract infections; cranberry, virulence, UPEC 
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4 Introduction 
Urinary tract infections (UTIs) are one of the most common infections found in humans and 
uropathogenic E.coli (UPEC) accounts for approximately 80% of all UTIs (Bien, et al., 
2012). Common symptoms include painful, frequent and urgent urination and can lead to 
irreversible kidney damage and even death (Flores-Mireles, 2015).  
It is thought that the main reason why UPEC is so successful, is their expression of a wide 
range of virulence factors (Bien, et al., 2012). Virulence genes are commonly located on 
mobile genetic elements such as pathogenicity islands, transposons, bacteriophages or 
plasmids and are generally spread by DNA horizontal transfer (Johnson, 1991). By 
understanding the role of virulence factors and their expression enables research aiming to 
discover novel therapeutic mechanisms that can limit bacterial infection.   
Virulence factors important to UPEC infection of the urinary tract include adhesins, 
capsules, toxins and iron-acquisition systems (Ranfaing, et al., 2018). These virulence 
factors contribute to the colonization and invasion of the urinary tract, leading to biofilm 
formation, tissue damage and ascension to the bladder and kidneys. Research suggests that 
adhesins, or fimbriae, are the most important virulence determinant in the infection of the 
urinary tract and have therefore been studied extensively (Bien, et al., 2012). 
It has been demonstrated that cranberries can decrease the virulence of UPEC, however 
little work has been completed on virulence factors other than adhesins. There are many 
cranberry products on the market, particularly cranberry capsules. For this study, the 
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cranberry capsule Cysticlean® was chosen. Cysticlean® capsules contain 240 mg of PACs 
and in vivo and in vitro results have shown a significant inhibition of adherence of E.coli to 
uroepithelial cells. A great improvement of symptoms has been seen, including the 
reduction in painful, frequent and urgent urination (Rodriguez, et al., 2015).  
This study focuses on the toxins SAT, and USP, the iron acquisition system ChuA, the 
protectins SoxS, KPSM, TraT and RecA, the antibiotic resistance gene CTX-M and the 
genes responsible for the normal function of the cell, IdfB and HcaT. In this study the CTX-
M producing E.coli isolate NCTC 1553 was analysed by qRT-PCR for the expression of 
virulence factors, before and after treatment with the cranberry product Cysticlean®. The 
results reported herein show that cranberry treatment reduces the expression of multiple 
virulence factors. These data suggest that cranberry’s mechanism may be multifaceted.     
4.1 Methods 
4.1.1 Bacterial Isolate and Cranberry Capsules 
Escherichia coli isolate NCTC 13353 expressing the resistance gene CTX-M-15 was used 
in all parts of this study. 
Cysticlean® capsules were purchased from VITA GREEN Europe S.A, which contained 
240 mg of PACs per capsule.  
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4.1.2 Minimum Inhibitory Concentration 
In order to determine the concentration of cranberry to use in the RT-qPCR experiment, the 
minimum inhibitory concentration was determined using the broth macrodilution method in 
duplicate. A 60mg/ml PAC stock solution in 20ml minimal medium (M9 Minimal Salts, 
5X, Sigma Aldrich, Dorset, UK) was created (recipe for minimal medium can be found in 
table 6-2 of Appendix). Serial dilutions in duplicate of the following concentrations of 
Cysticlean®: 30, 15, 7.5, 3.75, 1.88, 0.94, 0.47, 0.23, 0.12, 0.059, 0.029 mg/ml were 
created using M9 Minimal Salts 5X (Sigma Aldrich, Dorset, UK). An overnight culture 
(108 CFU/ml) of E.coli NCTC 1553 was diluted to 0.5 McFarland standard in minimal 
medium and 100 µl of this diluted culture was added to each concentration. Cultures were 
incubated at 37°C with shaking overnight. The MIC was determined as the lowest 
concentration with no visible growth. A positive control, consisting of minimal medium 
and E.coli and a negative control consisting of minimal medium only, were included. See 
6.7.1 of Appendix for more detail. 
4.1.3 RNA Extraction 
A 10ml volume of the MIC concentration was prepared in minimal medium. An overnight 
culture of E.coli NCTC 1553 was diluted to 0.5 McFarland standard and 100µl was added 
to the cranberry solution and incubated with shaking at 37°C for 4 hr. A second untreated 
culture was also incubated as an untreated control. A negative control consisting of minimal 
medium only was included.  All cultures were then filtered with a Whatman 1 and 0.45 
membrane (GE Healthcare Life Sciences, Buckinghamshire, UK) before RNA lysate was 
extracted using the Cells-to-CT™ 1-Step TaqMan™ Kit (ThermoFisher Scientific, 
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Loughborough, UK) following manufacturer’s instructions, except that the lysis + DNase 
time was doubled to 10 min. RNA concentration was measured using a Qubit 3 fluorometer 
(Thermofisher Scientific, Paisley, UK) (see figure 6-IV of Appendix).  The quality of RNA 
and any presence of DNA was assessed using agarose gel electrophoresis (see figure 6-2 
and 6.3.6 of Appendix). More detail of RNA extraction methods can be found in 6.3.4 of 
Appendix. 
4.1.4 Reverse Transcriptase qPCR (RT-qPCR) 
Primers and Taqman probes were designed using the PrimerQuest Tool (Integrated DNA 
Technologies) and can be found in table 5-1. More details of primer design can be found in 
6.4.3 of Appendix. As it is not possible to run melting curve analysis on Taqman assays, 
primer specificity was confirmed before RT-qPCR using agarose gel electrophoresis and 
extracted DNA (see figure 6-XI and 6.7.3 in Appendix). The Cells-to-CT™ 1-Step 
TaqMan™ Kit was used for RT-qPCR. More details on the Cells-to-CT™ 1-Step 
TaqMan™ Kit can be found in 6.7.2.  
PCR reactions were carried out using the PikoReal® 96 well Real Time-PCR platform 
(ThermoFisher, Loughborough, UK). PCR amplification reactions were performed using 
three technical replicates, in a volume of 10 µl containing 2.5 µl TaqMan® 1-Step qRT-
PCR Mix (initial concentration not known), final concentrations of 500 nM primers, 250 
nM probe and 1 μl of RNA lysate. Cycling parameters for the RT-qPCR assay were as 
follows: an initial reverse transcription step at 50 °C for 5 min, reverse transcriptase 
inactivation/initial denaturation at 95 °C for 20 s, followed by 40 cycles of 95 °C for 15 sec 
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and 60 °C for 1 min. A no-reverse transcriptase control was implemented in triplicate by 
adding the mastermix containing reverse transcriptase, after the reverse transcription step of 
the RT-qPCR assay. A no template control consisting of water instead of RNA, was also 
added in triplicate.  
 
 Table 4-1 Primers and probes used in this study. Primer and probe sets were designed using the PrimerQuest Tool 
(Integrated DNA Technologies). All probes contained a FAM fluorophore at the 5’ end and a black hole quencher at the 
3’ end. Gene 
 
 
 
 
 Forward Reverse Probe Product 
Size 
Reference 
16S GGAGACTGCCAGT
GATAAA 
GAGGTCGCTTCTCT
TTGT 
CCTTACGACCAGGGCT
ACACACGT  
113 This study 
KpsM GTTATATGGGACC
GTCATATT 
GCCACACTCTTTCG
TATC 
CCCAGAGCTTGCGGAT
TATCAATC 
125 This study 
ChuA CGATGGGCGAAAT
GTATAA 
GTTAGTTTCCGGAC
GTAAG 
TCTCGATTGGTCGCTT
CTATACCA 
98 This study 
CTX-M GAAAGCGAACCGA
ATCT 
GACATCGTCCCATT
GAC 
ACCTTGTTAACTATAA
TCCGATTGCGG 
101 This study 
SAT AGAAATATGGCAT
CTGTCACC 
CAGACGATATAGTC
GGTGTTTC 
CAGCAACCATTACTCT
GGGACAGC 
97 This study 
USP TGAGTTCTGGTATG
AGGAAGA 
CCCGTATGAACACC
ATACAC 
TACTGCCTGCTAGTGC
TTTCTGCC 
126 This study 
SoxS AGGGTTGATTACC
AGTATCC 
AACATATCGCAACA
CATCAC 
ACAGCGGCAATCAGC
GGCGATATA 
70 This study 
RecA GAGACAATTTGGT
ACTCCATC 
GATATCCAGTGAAA
GCGAAC 
CGCCTGGGTGAAGACC
GTTCCAT 
90 This study 
TraT AGATTGCAGAGCG
TACTAAG 
ACACGGGTCTGGTA
TTTATG 
CAACGGATAATGTTGC
CGCCCTGC 
127 This study 
IhfB GACGGTTGAAGAT
GCAGTAA 
CGGTAGTGCAAAG
AGAAACT 
AGCATATGGCCTCGAC
TCTTGCGC 
108 This study 
HcaT GGCATTATGGGAG
CAACTAC 
CTGGCGAGCAGCA
ATATAAC 
ACCACTATCAACCACG
GCAACGCC 
114 This study 
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4.1.5 Statistical Analysis    
The 16SrRNA gene was selected as a reference gene and the stability of expression was 
analysed using a t-test (see 6.7.5 for more details). The relative expression levels of the 
genes of interest compared to untreated samples were determined and normalized to the 
expression of the reference gene using a modified ∆∆Ct method to take into account primer 
efficiencies in Microsoft Excel. Primer efficiencies were calculated using serial dilutions of 
amplicons (diluted 1:1000) and this efficiency was used in ∆∆Ct calculations (see 6.7.6 for 
more details.  
All statistical analyses were carried out using the GraphPad Prism (version 5; GraphPad 
Software Inc.; La Jolla, CA, USA). To determine the significant differences between treated 
and untreated samples, the t-test was performed. A difference with a p-value of <0.05 was 
considered statistically significant. 
4.2 Results 
4.2.1 MIC 
The MIC for E.coli strain NCTC 13353 was determined to be 15mg/ml and this was used in 
all further experiments.  
4.2.2 RT-qPCR 
In this study, RT-qPCR was used to evaluate the impact of exposure of E.coli NCTC 13353 
cells to the commercial cranberry product Cysticlean® (at MIC; for 4h) on the expression 
of ten genes that have been shown to be associated with the virulence and fitness of UPEC. 
The selected genes included the toxins SAT, and USP, the iron acquisition system ChuA, 
the protectins SoxS, KPSM, TraT and RecA, the antibiotic resistance gene CTX-M and the 
 117 
genes responsible for normal function of the cell, IdfB and HcaT. Figure 4-I shows the 
average Ct values, as a measure of expression, of these 10 genes in the absence or presence 
of cranberry pre-treatment. There was a significant decrease (P < 0.05) in the Ct value for 
each gene in the presence of cranberry, indicating a decrease in expression.  Figure 4-II 
shows the decrease as a Double Delta Ct Value (ΔΔCt) -1. By presenting the data as ΔΔCt) 
-1 a value of 0 would indicate no change while a value between 0 and 1 indicates a 
downregulation in expression. The t-test showed that all the genes tested were significantly 
downregulated (P < 0.05) following treatment with cranberry.  
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Figure 4-I Virulence genes tested. Genes for toxin production, iron acquisition, antibiotic resistance protectins and normal 
function of the cell were tested after exposure to Cysticlean® using RT-qPCR all genes were significantly downregulated 
when tested using a t-test. * p = 0.01 to 0.05 ** p = 0.001 to 0.01 *** p = < 0.001 ns = not significant. 
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Figure 4-II The expression fold change of genes antibiotic resistance, iron acquisition, toxins, protectins and genes 
responsible for the normal function of the cell. The results of the expression fold change were normalized against the 
reference gene 16s and then were taken away from one to show the genes were downregulated.  
It is not possible to run melting curve analysis on Taqman assays, due to the degenerate 
nature of Taqman probes. Non-specific products do not produce results in Taqman assays, 
therefore it is not necessary to run products on an agarose gel. However, non-specific 
products should be avoided as they reduce the efficiency of the reaction. Taqman assays 
should be checked for specificity before running qPCR (see figure 6-XI and 6.7.3 in 
Appendix). 
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4.3 Discussion 
Reports have shown that numerous genes are implicated in the virulence and fitness of 
UPEC, therefore downregulating the expression of these genes could add to the efficiency 
of antibiotic treatment and could reduce the likelihood of treatment failure (Wasfi, et al., 
2016). In this study, ten genes playing significant roles in the normal function of the cell, 
iron acquisition, toxin production and stress survival in E. coli were tested after exposure to 
the cranberry product Cysticlean ® and the relative gene expression was determined using 
qRT-PCR. Cysticlean® contains concentrated American cranberry extract, equivalent to 
240mg of proanthocyanins (PAC). 
The current results show that Cysticlean® significantly reduces the expression of a wide 
variety of genes responsible for fitness and virulence. This is the first study to access the 
effect of Cysticlean® on the expression of virulence and antibiotic resistance determinants. 
Even though it was the least downregulated gene, it could be stipulated that the most 
important downregulation was that of the CTX-M gene that causes extended-spectrum-β-
lactamase (ESBL) production. ESBL-producing UTIs are a major problem in both the 
community and the hospital (Esteve-Palau, et al., 2015). The reduction in expression of this 
gene could lead to increased susceptibility of previously resistant isolates.  
Reports have suggested that USP functions as a bacteriocin, targeting competing bacterial 
strains (see figure 4-III). It has also been shown to enhance infectivity in the urinary tract 
and play a role in UPEC pathogenesis (Crnigoj, et al., 2014; Paniagua-Contreras, et al., 
2017; Tiba, et al., 2008). In a study by Bauer et al, results showed that the USP gene was 
found in 80% of cystitis isolates. (Bauer, et al., 2002). A reduction in the expression of USP 
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could lead to the outcompeting of this bacteria by other non-pathogenic bacteria and a 
reduction in its ability to cause pyelonephritis.  
It is especially advantageous for UPEC to be able to utilize heme and/or hemoglobin, as the 
urinary tract is naturally low in iron. UPEC secrete cytotoxins that can access the heme 
reservoir within cells. These two capacities combined, could aid iron acquisition throughout 
the infection process (Subashchandrabose & Mobley, 2015). ChuA is an outer membrane 
receptor responsible for the transport of heme into the cell for utilization as iron (see figure 
4-III) (Nagy, et al., 2001). Reduction in iron transport into the cell could lead to reduced 
growth of the bacteria or even cell death. Studies have shown that cranberry causes the over 
expression of iron-acquisition genes. In a study, cranberry treatment caused an up-
regulation of genes encoding iron metabolism regulators (fur), transport protein (feoAB), 
genes involved in biogenesis pathway of Fe-S cluster (iscAS) and iron storage (ftnA, acnA, 
sodB) (Ranfaing, et al., 2018). This is the first study to investigate the expression of the 
ChuA gene after exposure to a cranberry product. Combining the literature with the results 
of this study, cranberry causes the over expression of iron-acquisition genes, but a 
downregulation of heme membrane receptors. It has been suggested that the expression of 
ChuA is influenced by RfaH in UPEC (Nagy, et al., 2001). Therefore, it may be that 
Cysticlean® has an effect on RfaH and this needs to be investigated further.  
SAT is a serine protease, which is found predominantly in uropathogenic strains of E.coli, 
which has been shown to elicit a cytopathic effect on cultured epithelial cells (see figure 4-
III). It has also been shown to be associated with pyelonephritis (Subashchandrabose & 
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Mobley, 2015). A reduction in the expression of this gene could lead to a reduction in the 
ability of UPEC to cause pyelonephritis.  
KpsM is responsible for capsule production, protecting the bacterial cell from host defenses 
such as engulfment by phagocytes and the bactericidal effect produced by the complement 
system (see figure 4-III). KpsM is commonly associated with pyelonephritis (Paniagua-
Contreras, et al., 2017). A downregulation in the expression of this gene could lead to cell 
death by phagocytes and the complement system. 
 SoxS increases tolerance to stress, activated by cytotoxic weapons produced by the human 
immune system such as nitric oxide and leads to direct activation of antibiotic resistance 
factors (see figure 4-III) (Warner & Levy, 2012). Reduction in the expression of soxS could 
lead to bacteria that are less tolerant to stress and generally less antibiotic resistant. In a 
study, cranberry treatment caused significant over-expression of genes involved in stress 
response (arcA, rpoS, cpxR), periplasmic stress (rseAC) and oxidative stress (oxyR). This 
being said, they did not specifically report results on the SoxS (Ranfaing, et al., 2018). 
RecA plays a role in DNA recombination, by catalyzing the homologous pairing driven by 
ATP and strand exchange of DNA molecules (see figure 4-III) (Greene, 2016). A reduction 
in recombinational repair could lead to bacteria that are less able to survive. 
TraT is an outer membrane lipoprotein that is responsible for preventing unproductive 
conjugation between bacteria carrying like plasmids (see figure 4-III). It has also been 
shown to interfere with complement-mediated killing, imparting a mild amount of serum 
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resistance (Johnson, 1991). A downregulation in the expression of this gene could lead to 
an increase in unproductive conjugation and a decrease in serum resistance.  
The HcaT gene plays a role in the catabolism of 3-phenylpropionate and cinnamic acid, the 
products of which are fed into the mhp pathway (see figure 4-III). IhfB is responsible for 
the activation of transcription via sequence-specific DNA-binding and for site-specific 
recombination. It is uncommon to see changes in expression of these genes, in fact they 
have been recommended as suitable reference genes in transcriptional analysis of E.coli 
(Zhou, et al., 2011). This suggests that the effect of Cysticlean® is multifactorial, effecting 
many different pathways. 
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Figure 4-III Reported mechanisms of action for 10 Virulence genes in Escherichia coli are downregulated by 
Cranberry treatment. Various virulence factors are established to enhance the pathogenicity of UPEC. This study has 
shown that the following 10 genes, which all encode for virulence factors with different mechanisms, are all 
downregulated by cranberry treatment. These data suggest that cranberry’s antimicrobial action is multifaceted. Below is a 
summary of the action of each gene downregulated by cranberry.1) Uropathogenic specific protein gene (USP) is a 
Bacteriocin that possesses DNase activity that can degrade plasmid DNA of competing uropathogens. 2)  chuA is an outer 
membrane protein that plays a key role in heme uptake. 3) hcaT encodes a potential permease for the uptake of 
phenylpropionic acid (PP), an aromatic acid that can be utilised as a carbon and energy source. 4) kpsM protein plays a 
role in group 2 capsular polysaccharide synthesis. 5) IhfB is a specific DNA-binding protein that functions in genetic 
recombination as well as in transcriptional and translational control. 6) recA catalyses ATP-driven homologous pairing 
and strand exchange of DNA molecules necessary for DNA recombinational repair. 7) SoxS protein is a transcriptional 
activator of the superoxide response regulon of E.coli. 8) traT prevents unproductive conjugation between bacteria 
carrying like plasmids. 9) CTX-M produces beta-lactamases that can render beta-lactams inactive. 10) Sat is a 
secreted autotransporter toxin exhibits cytopathic activity and loosening of cellular junctions.  
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Other studies have shown that exposure of UPEC to cranberry PACs or cranberry powder 
results in the downregulation of the flagellin gene fliC which results in impeded motility 
via swimming and swarming. Honey has also been shown to have a similar effect of 
virulence genes to cranberry, however its ability to reach the urinary tract intact has been 
questioned (Wasfi, et al., 2016). 
In vivo studies have previously been conducted on Cysticlean®. In experiments conducted 
with rats, urine samples taken after treatment with Cysticlean® capsules (118 mg PACs/ 
animal) showed a significant inhibition of E. Coli adherence. Many cranberry extracts 
available in the market, but, Cysticlean® sachets and capsules have shown the highest 
inhibition on bacterial adherence to urinary tract epithelium, and their use is related to a 
high tolerability, treatment compliance and effectiveness in preventing UTI. Cysticlean® 
has also been clinically proven to be highly effective in helping to reduce UTIs recurrence 
after 3-6months (Rodriguez, et al., 2015).  
4.3.1 Mechanism of action 
Two complementary mechanisms have been suggested to explain the ability of the 
American cranberry to reduce urinary tract infections. The first mechanism has been 
credited to its biocidal activity, through the production of several elements that can damage 
bacteria. The second mechanism is attributed to its anti-virulence activity, through the 
downregulation and interference of multiple virulence factors associated with tolerance to 
stress and survival in the urinary tract. The latter could ultimately result in the weakening of 
bacterial survival abilities and its ability to cause infection (Wasfi, et al., 2016).  
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Recurrent UTI is commonly treated with antibiotic prophylaxis, which has been shown to 
attribute to bacterial resistance (Othman, 2016). Antibiotic resistance is a major concern 
worldwide, therefore a re-evaluation of the treatment recommendations for UTI should be 
considered. An alternative to antibiotic prophylaxis could be treatment using cranberry 
products or a combination of cranberry and antibiotic treatment in an attempt to reduce 
resistance rates in UTIs. 
Future studies should investigate the effect of Cysticlean® on other virulence and antibiotic 
resistance determinants and other bacterial species that cause UTI to combine with in vivo 
studies that have already been carried out. The effect of a cranberry and antibiotic 
combination should be considered further. 
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5 Overall Discussion 
5.1 Summary of Research  
In this PhD project, I have used molecular microbiology methods to investigate four main 
areas of interest. Firstly, a study was carried out to investigate the prevalence of the ESBL 
family in the Leicestershire area and the relationship between plasmids and antibiotic 
resistance determinants. Given the high levels of ESBLs found in this study, a clear need 
was identified for a rapid test to detect ESBLs in the clinical laboratory. This lead to the 
development of a qualitative real-time PCR based method to detect 149 variants of the 
ESBL family in UTIs. It was also identified that alternatives to antibiotics are going to be 
required in an effort to counteract antibiotic resistance. In this study, the potential effect of 
the commercial product Cysticlean® on virulence factors associated with UTI was 
investigated. It was found that Cysticlean® is effective in reducing the expression of a wide 
variety of virulence factors and the CTX-M gene coding for beta-lactam resistance.  
The results from these studies shall be discussed in the broader context of antibiotic 
resistance as a whole; and the challenges that face us in tackling it; including prevalence 
studies, rapid diagnostics, economics and treatment development.  
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5.2 Antibiotic Resistance 
The 21st century has seen antibiotic resistance rise to be a major public health concern that 
threatens the effective prevention and treatment of a growing number of bacterial infections 
(Prestinaci, et al., 2015). The O’Neill report in 2016 reiterated the importance of the threat 
of antibiotic resistance and proposed many actions, including strengthening surveillance 
systems, the development of rapid diagnostics, and investment in new classes of antibiotics 
and alternatives (O'Neill, 2016). 
5.3 Surveillance of Antibiotic Resistance 
Surveillance of antibiotic resistance is vital in order to provide information on the scale and 
trends in resistance and to monitor the impact of interventions (Johnson, 2015; O'Neill, 
2016; World Health Organization, 2001). The level at which data is collected (local, 
national or international) will determine the action required. Clinical management, 
treatment guidelines and infection control policies should be guided by frequent local 
prevalence data, as well as to educate prescribers (World Health Organization, 2001). 
Frequent prevalence information ensures that policy changes are made in a timely manner, 
as the speed of antibiotic resistance tends to be faster than policy change implementation 
(O'Neill, 2016). At a national level, collected data may also be used to inform policy, but 
also to update lists of essential antibiotics, treatment guidelines and the evaluation of cost-
effectiveness interventions (World Health Organization, 2001). As antibiotic resistance is a 
global problem, international collaboration will always be needed in surveillance (O'Neill, 
2016). There are gaps in knowledge of the extent of resistance in many parts of the world, 
due to the absence of suitable surveillance. 
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It is the hoped that the prevalence study completed as part of this PhD, can contribute to 
surveillance data in the UK and worldwide, and can help inform local antibiotic 
stewardship policy. It is also hoped that prevalence data on the levels of antibiotic 
resistance in farming, the environment and companion animals in the area will be combined 
with this study and others like it to give a true One Health perspective of the problem of 
antibiotic resistance. 
As mentioned previously, Leicester has a high immigrant population and it was suggested 
that this may have contributed to the high level of CTX-M found. The findings of this study 
reinforce the need for a worldwide collaboration on antibiotic stewardship, as the actions of 
other countries can have a profound effect on antibiotic resistance levels on other countries 
through immigration. 
Without adequate surveillance, the majority of attempts to prevent or reduce antibiotic 
resistance will become increasingly more difficult (World Health Organisation, 2014). 
Surveillance data can only be effective if it is acquired in an adequate amount of time. The 
development of rapid diagnostics is essential for not only patients, but to speed up the 
processing of surveillance isolates (O'Neill, 2016). 
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5.4 Rapid Diagnostics 
The issue with current diagnostic methods is that they can give results conclusively, but not 
rapidly. Most methods are still based upon those developed by Louis Pasteur and Robert 
Koch in the nineteenth century (O'Neill, 2015). Current laboratory tests require at least 36 
hours to give a result that can be used to guide antibiotic treatment. This is far too long and 
empirical treatment will have been started long before the result has been achieved, 
possibly with ineffective antibiotics due to resistance, or with unnecessarily broad-spectrum 
antibiotics, increasing the chance of resistance developing in the future (Lupo, et al., 2013; 
O'Neill, 2015).  
It is well known that without rapid diagnostics, it is far more difficult to prescribe the right 
antibiotic to the right patient in a timely manner (Lupo, et al., 2013; O'Neill, 2015). This 
problem has largely been overcome in the treatment of long-term infections such as 
tuberculosis or HIV, where in higher income countries at least, patients are tested for 
resistance before treatment in started, not after (O'Neill, 2015). It is therefore surprising 
there is a lack of rapid diagnostics to achieve this with other bacterial infections.  
5.5 Challenges in Developing Rapid Diagnostics for Bacterial Infections 
There are many barriers to overcome in the development of bacterial diagnostics 
(Davenport, et al., 2017). Unfortunately, there is a lower level of public funding for the 
development of diagnostics for bacterial infections (O'Neill, 2015). Diagnostics for 
bacterial infections also have other challenges, when compared to other infections. The 
main problem is that many bacterial pathogens can be present without necessarily causing 
infection and so it is difficult for diagnostics to distinguish between harmless bacteria and 
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those that are causing infection. It is estimated that a third of people carry Staphylococcus 
aureus in their nose with it causing an infection, and therefore do not need antibiotics. On 
the other hand, if HIV is present in a patient, it is obvious that they require treatment. This 
makes it especially difficult to develop diagnostics for bacterial infections (O'Neill, 2015).  
The cost of rapid diagnostics is also considered another barrier, especially by prescribers 
(O'Neill, 2016; Ivanov, 2013). Most antibiotics are far less expensive that rapid diagnostic 
tests, therefore it is seen as an additional cost to diagnose infections before giving treatment 
(Ivanov, 2013). However, this way of thinking is very narrow minded, as it is evident that 
whilst the upfront cost is higher, both patients and healthcare systems benefit financially 
from rapid diagnostics. This opinion is not yet widespread, meaning that there are rapid 
diagnostics ready to come to market, that are not being bought and some that have been 
bought and not used. 
Rapid diagnostics that allow the right antibiotic to be given to the right patient quickly, will 
likely help save money several ways. This includes reducing the length of stay in hospital 
for patients with bacterial infections and identifying those with antibiotic resistant 
infections so that infection control measures can be put in place to prevent spread. Infection 
control measures are expensive and rapid diagnostics could mean that precautionary 
measures put in place for high risk patients could be stepped down much more quickly 
(Bauer, et al., 2014). This was found to be the case in a study in the Netherlands, it was 
found that rapid diagnostics could reduce demand on intensive care isolation rooms by at 
least 40% (Wassenburg, et al., 2012).  
 133 
On the other hand, it is common that diagnosis based on symptoms alone could miss out 
giving antibiotics to a patient that did in fact need them. Without antibiotics, the patient 
may deteriorate and end up in hospital, leading to much higher costs than using a rapid 
diagnostic test (Llor & Bjerrum, 2014).  
Another benefit is the potential to alleviate some of the pressure on healthcare systems and 
save valuable doctor’s time in surgeries by allowing screening to be completed in 
pharmacies or even at home. In some countries a diagnostic test for strep throat is available 
in some pharmacies. If the diagnostic test indicates that the infection is likely to be 
bacterial, the pharmacist can prescribe antibiotics for the patient, rather than the patient 
seeing a doctor (Thornley, et al., 2016). 
There is clearly a need for rapid diagnostics that can be implemented throughout both high 
and low-income countries (Bauer, et al., 2014; Ivanov, 2013; World Health Organization, 
2001). In the near future, rapid diagnostic tools should be point of care (at the bedside, in a 
doctor’s office, pharmacy or at home), should be able to give meaningful information 
(bacterial or viral infection and resistance profiling) and should be combined with computer 
programming such as artificial intelligence that can access electronic medical records, 
combined with the symptoms that the patient is suffering, relevant and up to date literature 
and the latest local surveillance data, to assist doctors in recommending treatments. The 
information obtained by rapid diagnostics should immediately feed into real-time 
surveillance data for local, national and international infectious disease and antibiotic 
resistance, to monitor trends and enable the prediction of emerging problems so that 
interventions can be put in place rapidly. 
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Whilst the diagnostic method developed in this study does not fully fulfill these criteria, it 
is an important stepping stone in providing doctors with the most information currently 
available to aid them in suggesting treatment for a patient. With further optimization, this 
method could help antibiotic stewardship by reducing the time taken to get an antibiotic 
sensitivity result, helping to reduce resistance rates. It could also reduce the time patients 
spend in hospital, easing the bed crisis in the NHS and reduce the chance of infection 
spread within hospitals. Another benefit could be the opportunity to step down infection 
prevention measures earlier. If the method could be optimized for use in low-income 
countries, such as India, that have a huge problem with Cephalosporin resistance, this could 
improve healthcare dramatically. Infectious diseases are still a significant limitation in 
improving life expectancy in low income countries. In 22 countries, 70% or more of 
premature deaths are still caused by infectious diseases and related conditions. If methods 
such as this could be used in the developing world to detect infectious diseases earlier than 
current methods, this could go some way to improve life expectancy. All of this combined 
could not only save the NHS millions, but also give the world a fighting chance at tackling 
antibiotic resistance.  
5.6 Alternatives to Antibiotics 
There is clearly an awareness of the need for new antibiotics and alternatives to antibiotics, 
signified by the fact that there are antibiotics and vaccines in clinical trial at present 
(Flores-Mireles, 2015; O'Neill, 2016). However, antibiotic stewardship is understandably 
concerning to pharmaceutical companies, as this may have a negative impact on sales 
(O'Neill, 2016). This may lead to companies reducing their investment in antibiotic 
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research and development and may decrease the amount of antibiotics and vaccines that 
they donate, or reduce the cost of, to low income countries. 
Cranberry is one alternative to antibiotics that was studied as part of this thesis and in light 
of the results, should be given more attention and moved from the “old wives tale” thinking 
into a potential therapeutic option. Cranberry, either as juices, powder or capsules, has been 
shown to be safe, effective and synergistic with antibiotics (Hisano, et al., 2012). This 
treatment could be most effective with antibiotic resistant UTIs, as this study has shown 
that it can reduce the expression of CTX-M in E.coli. If this is also true of other antibiotic 
resistance genes, cranberry could be a viable alternative to antibiotics for treatment of UTI, 
especially in those with recurrent infections. In this study, the effect of a cranberry capsule 
Cysticlean® was shown to decrease the expression of some key virulence genes linked to 
urinary tract infection caused by E.coli. It can be suggested that targeting some of these 
virulence factors or others, could be a potential treatment of UTI.  
The development of vaccines is another possible alternative and there are vaccines 
currently undergoing clinical trial. Despite research that suggests that a prior UTI does not 
produce a protective immune response, animal model studies indicate that immunization 
with UPEC antigens can stimulate a mucosal immune response that may prevent UTI. 
However, the heterogenicity of uropathogens means that vaccine design is complicated and 
requires more research for an effective UPEC vaccine to be developed (Flores-Mireles, 
2015). Vaccines currently under investigation include those that target adhesins, exotoxins, 
iron acquisition systems, flagella, capsule, and lipopolysaccharides.  
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Another alternative to antibiotics that may have merit is antimicrobial peptides. 
Antimicrobial peptides are natural components of the innate immunity of many plants and 
animals. Like cranberry, antimicrobial peptides kill bacteria by multiple mechanisms and 
this includes membrane pore formation. They are also synergistic with antibiotics (Flores-
Mireles, 2015). However, resistance mechanisms have already been identified, and 
improvements in bioavailability, stability and reduced toxicity are required before these can 
be available for treatment (Fuente-Núñez, et al., 2012). Further research is needed; 
however, these provide promising alternatives to antibiotics.  
5.7 Future Work 
5.7.1 Prevalence 
Prevalence studies are an important part of tackling antibiotic resistance and should be 
continued regularly. Other resistance mechanisms should be monitored in the Leicestershire 
area, such as carbapenamases, and should not be limited to humans; isolates from the 
environment, animals and livestock should always be included in surveillance data as well. 
As mentioned previously, in the future surveillance data should be real-time and combined 
with artificial intelligence in order to analyse it rapidly. Some work has gone into this, with 
the establishment of EARS-Net and GLASS, however results are not published fast 
enough. For example, using EARS-Net, results for third generation cephalosporin 
resistance in E.coli in the UK were only available up to 2016. The improvement of rapid 
diagnostics should go some way in speeding up this process.  
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5.7.2 Rapid Diagnostics 
As mentioned previously, the optimization of the diagnostics method developed in this 
study could have great benefit. In order to optimize this method, other antibiotic resistance 
genes should be added to the genetic profile such as those that code for carbapenamases. In 
order for this to be achieved, certain limitations need to be overcome. This method takes 
advantage of the use of channels that multiplex real-time PCR machines use to detect 
fluorescent chemistry such as the one used in this study. The PCR instrument used here 
(Pikoreal ThermoFisher Scientific, UK) has four channels, and therefore can only multiplex 
four different products in one well. However, advancements in technology has led to the 
development of real-time PCR instruments that can multiplex to a much higher level, such 
as the Quant Studio 12K flex qPCR instrument that can multiplex up to 21 genes at a time.  
It was also mentioned that optimization is required for use in low income countries. With 
the development of microfluidics and biosensors, it is possible that the time to detection for 
this method could be reduced further and incorporated into a small stand-alone device that 
could be used in the field, in doctor’s offices etc. The invention of new types of DNA 
polymerases that are much cheaper to manufacture, could mean that this method becomes 
far cheaper to run and attainable to low income countries.    
Currently, this method requires pathogen identification and culture. Ideally this method 
should be optimized for use straight from urine, and there are now DNA extraction kits that 
can potentially do this. This still leaves the issue of pathogen identification, as urine 
samples can contain a large number of contaminants and bacteria that are not causing harm. 
Therefore, it is suggested that this method be combined with one that can identify the 
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causative agent. Research has already gone some way in developing qualitative real-time 
PCR methods that can identify pathogens, with a semi-quantitative method (a threshold for 
Ct method indicates infection) having already been developed.  
Ideally the results from this method, where possible, should be automatically uploaded to 
surveillance databases, in order for real-time surveillance to be achievable. 
Alternative forms of PCR include loop-mediated isothermal amplification (LAMP) and 
recombinase polymerase amplification (RPA). Whilst LAMP is cost-effective and rapid, 
due to the isothermal nature of BST polymerases, primer design is far more laborious and 
false positives can be a significant problem. In addition, multiplexing LAMP assays is very 
difficult to achieve (Mayboroda, et al, 2018). RPA is another isothermal form of PCR, than 
can achieve results in as little as ten minutes. However, currently all RPA kits are produced 
under the license of TwistDx Limited (Cambridge, UK), meaning that optimisation of 
assays is more difficult (Mayboroda, et al, 2018). If the issues with these methods can be 
overcome, they would become ideal for the development of diagnostics. 
5.7.3 Cranberry  
Further research on the use of cranberry as an alternative to antibiotics/in combination with 
antibiotics should be conducted. This should involve testing more virulence and antibiotic 
resistance genes; a microarray analysis may be more useful in doing this. This should also 
be combined with phenotypic and in vivo studies, to give a broad overview of the effect that 
cranberry treatment has. Other bacterial strains and species as well those that are antibiotic 
resistant and non-resistant, that cause UTI should be studied to see if the effect of cranberry 
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is broad-spectrum. Cranberry should be studied for the effect on other infections. For 
example, could it be used to treat wound infections in the same way as honey?  
In this study, only one reference gene was able to be used. Multiple reference genes 
increase the accuracy of relative expression normalization and allows for the quality control 
on the stability of the reference gene expression. Therefore, the use of one reference gene is 
a limitation of this study.  
This study has focused on ESBL-producing UTIs. This is only one of numerous antibiotic 
resistant infections that are of major concern, and it is likely that many more will emerge in 
the future. Many more studies like this one are required all over the world in order to tackle 
antibiotic resistance. 
5.8 Concluding Remarks 
This study shows that antibiotic resistance is a complicated and multifaced problem that 
requires more than one effort, in combination. However, results from this study 
demonstrate that it is possible to make a difference to antibiotic resistance. Here the 
prevalence of ESBLs in the local area was studied, and suggestions have been made to 
improve surveillance. A rapid qualitative real-time PCR method to detect ESBLs in UTIs 
was developed that, with optimization, could see a real benefit to patients. The effect of the 
cranberry product Cysticlean® was tested by qRT-PCR and it was found that it reduced the 
expression of virulence genes associated with UTI infection and the antibiotic resistance 
gene CTX-M. 
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6 Experimental Development and Rationale 
6.1 Isolate Collection 
Bacterial isolates (n=236) of Enterobacteriaceae isolated from urinary tract infections in 
the form of bacteria on agar plates, were obtained from the Leicester Royal Infirmary 
hospital (Leicester, England) on a weekly basis. These isolates were then sub-cultured onto 
Müller-Hinton agar (Oxoid, Basingstoke, UK) plates for 24 hours at 37°C. Bacterial 
isolates were stored at -20°C in 50% glycerol stocks. Glycerol stocks were made by adding 
250 µl distilled water to 250 µl glycerol and autoclaving. 500 µl of overnight nutrient broth 
(Oxoid, Basingstoke, UK) culture was then added. A total of 181 of these isolates were 
used in the Real Time-PCR assay development.  
Five control isolates were obtained from Public Health England, that can be found in table 
6-1. These were stored on cryogenic protect beads (Scientific Laboratory Supplies, 
Loughborough, UK). One set was stored at -20°C for working stocks and one set was stored 
at -80°C for creation of future working stocks. These control isolates were used in both the 
prevalence study and the development of the qualitative real-time PCR assay. NCTC 13353 
was also used in the qRT-PCR study.  
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6.1.1 Bacterial Strains 
Table 6-1 Five control isolates were obtained from Public Health England used in this study.  Strains, the species of 
bacteria and the antibiotic resistance gene expressed are shown. 
 
6.2 Recipes 
This study used several different solutions for the growth and maintenance of bacteria or 
during RNA extraction and RNA or DNA detection. The formulation of each solution is 
outlined in table 6-2.   
Table 6-2 The formulations of the different media used in this study. Ethylenediaminetetraacetic acid (EDTA).   
Name Formulation g/litre 
Nutrient broth 1.0 “Lab Lemco” powder, 2.0 yeast extract, 
5.0 peptone, 5.0 sodium chloride 
Muller Hinton agar Beef, dehydrated infusion from - 300.0, 
Casein hydrolysate - 17.5, Starch - 1.5, 
Agar - 17.0 
Minimal medium Disodium Phosphate Heptahydrate 25.6, 
Monopotassium Phosphate, Sodium 
Chloride 1, Ammonium Chloride, 20 mL of 
20% D-Glucose solution, 2 mL of 1.0 M 
MgSO4 solution, 0.1 mL of 1.0 M CaCl2 
solution 
PBS Sodium chloride - 8.0, Potassium chloride - 
0.2, Disodium hydrogen phosphate - 1.15, 
Potassium dihydrogen phosphate - 0.2 
LB broth (miller) Tryptone - 10, NaCl - 10, Yeast Extract – 
5.0 
MacConkey agar Peptone - 20.0, Lactose - 10.0, Bile salts - 
5.0, Sodium chloride - 5.0, Neutral red - 
0.075, Agar - 12.0 
10x TBE buffer 89mM Tris, 89mM Boric acid, 2mM EDTA 
Strain name Antibiotic resistance gene expressed Bacteria 
NCTC 13353 CTX-M-15 Escherichia coli 
NCTC 13351 TEM-3 Escherichia coli 
NCTC 13368 SHV-18 Klebsiella pneumoniae 
NCTC 13442 OXA-48 Klebsiella pneumoniae 
NCTC 10418 Negative Escherichia coli 
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6.3 DNA, RNA and Plasmid Extraction  
6.3.1 DNA Extracted from Colonies 
DNA for use in 2.1.2 and 3.1.1 was extracted by the boiling method (figure 6-I). DNA 
extractions were stored at -20°C.  
Figure 6-I The boiling method used to extract DNA from bacterial isolates.  Each isolate was sub-cultured onto Muller 
Hinton agar and incubated for 24 hr at 37 °C. Colonies were then picked from the agar plate and suspended in sterile 
distilled water and mixed by vortexing. This suspension was then heated in a dry bath for 10 min at 94 °C before being 
used in PCR reactions. 
6.3.2 Plasmid Extraction for Replicon Typing 
Each isolate was sub-cultured in LB broth overnight at 37°C. Plasmids were extracted 
using the Illustra PlasmidPrep Mini Spin Kit (GE Healthcare Life Sciences, 
Buckinghamshire, UK). One colony was suspended in 10 ml nutrient broth (Scientific 
Laboratory Supplies, Loughborough, UK) and grown overnight at 37°C. 1.5ml of this 
culture was transferred into a microcentrifuge tube and centrifuged at full speed for 30 
seconds using a Sigma 1-14 microcentrifuge (Sigma Zentrifugen, Osterode am Harz 
Germany). The supernatant was discarded, and the pellet was re-centrifuged at full speed 
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for 30 seconds. A pipette was used to remove any remaining supernatant. A total of 175 µl 
of lysis buffer type 7 was added to the pellet and resuspended by vortexing using a 
Fisherbrand™ ZX3 Vortex Mixer (Fisher Scientific, Loughborough, UK). A total of 175 µl 
of lysis buffer type 8 was then added and this time mixed by inversion until the solution 
became clear. Vortexing would have sheared the genomic DNA and contaminated the final 
purification. It was also important to complete both lysis steps within 5 minutes, as the 
NaOH will denature plasmids above this time. The resulting mixture was then centrifuged 
at full speed for 4 minutes. The supernatant was then transferred to a collection tube, 
containing one Illustra plasmid mini column and centrifuged at full speed for 30 seconds. 
Flow through was then discarded. The column was then washed with 400 µl of lysis buffer 
type 9 and centrifuged at full speed for 30 seconds. Flow through was discarded once again. 
400 µl of wash buffer type 1 was added to the column and centrifuged for 1 minute. Flow 
through and collection tube was discarded. The Illustra plasmid mini column was 
transferred into a fresh Microcentrifuge tube and 100 µl of elution buffer type 4 was added 
directly to the centre of the column. This was then incubated for 30 seconds at room 
temperature and then centrifuged at full speed for 30 seconds. The flow through was then 
stored at -20 °C. 
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6.3.3 Purified DNA extraction  
DNA was extracted using the Illustra bacteria genomicPrep Mini Spin Kit (GE Healthcare, 
Buckinghamshire, UK). One colony was suspended in 10 ml nutrient broth (Scientific 
Laboratory Supplies, Loughborough, UK) and grown overnight at 37°C. 1 ml of this culture 
was transferred into a Microcentrifuge tube and centrifuged at full speed for 30 seconds. 
The supernatant was discarded. 40 µl of lysis buffer type 2 was added and mixed by 
vortexing until completely resuspended. 10 µl of proteinase K was added and mixed by 
vortexing for 10 seconds. 10 µl of lysis buffer type 3 was added and vortexed for 10 
seconds to mix and then centrifuged for 5 seconds at 1000 x g to collect the sample at the 
bottom of the tube. This was then incubated for 7 minutes in a dry bath at 55 °C. After the 
incubation, the sample was vortexed and centrifuged for 5 seconds at 1000 x g to collect the 
sample in the bottom of the tube. This was then incubated for another 8 minutes and 
centrifuged again for 5 seconds at 1000 x g. 500 µl of lysis buffer type 4 was added and 
mixed by vortexing for 10 seconds, then incubated at room temperature for 5 minutes. After 
the incubation step, the sample was vortexed and centrifuged for 5 seconds at 1000 x g, 
then incubated again for 5 minutes at room temperature. The samples were then added to a 
collection tube, containing a bacteria mini column and centrifuged for 1 minute at 11000 x 
g. The flow through was discarded. 500 µl of lysis buffer type 4 was added to the column 
and centrifuged for 1 minute at 11000 x g, and the flow through was discarded. 500 µl of 
wash buffer type 6 was added to the column and centrifuged for 3 minutes at 16000 x g. 
The bacteria mini column was then transferred to a fresh Microcentrifuge tube and 200 µl 
of elution buffer type 5, pre-heated to 70 °C in a dry bath was added directly to the centre of 
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the column. This was then incubated for 1 minute at room temperature and centrifuged at 
1000 x g for 1 minute. The flow through was then stored at -20 °C.  
6.3.4 RNA Extraction Method Development for RT-qPCR 
Different growth stages were tested to see which gave the best results. X106, x107, x108 and 
x109 CFU/ml were tested. X109 CFU/ml gave the best results. RNA was extracted by the 
method below and the resulting RNA was analysed for quality by agarose gel 
electrophoresis using the method outlined below. Upon analysis of the gel result, there 
appeared to be DNA contamination in the RNA product (figure 6-II). In order to improve 
this, the standard lysis time and DNase was doubled to 10 min. DNA contamination on the 
gel disappeared.  
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Figure 6-II Optimisation of RNA extraction protocol. A) shows the first attempt at RNA extraction. DNA contamination 
appears to be highly present, in the form of a bright band in the well of the gel. B) shows RNA extraction after the 
doubling of the combined lysis and DNase time from five to ten minutes. M indicates the DNA ladder. The band in the 
well of the gel has disappeared and there are two distinct bands clearly present. 
 
The first run on the qPCR with the 16S gene showed quite a high Ct (figure 6-III), so it was 
determined that less RNA was needed in the reaction.  
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Figure 6-III Initial run of RT-qPCR protocol with the 16S gene and a negative control.  It was determined that the Ct of 
this first run was too high, and less RNA was need in future experiments. 
 
During the MIC testing, it became quite clear that the cranberry extract would be an issue 
in qPCR testing, due to its colour and viscosity, and this would need to be filtered out. 
Filtering did significantly reduce the concentration of RNA achieved, however as the 
concentration needed to be reduced anyway, this was not an issue. Filtering did not appear 
to have an effect on the quality of RNA. The untreated and treated samples yielded slightly 
different RNA concentrations, and this was calculated so that the same amount of RNA was 
added in the RT-qPCR reaction. 
In the final protocol, one colony of NCTC 1553 CTX-M-15 producing E. coli bacteria was 
added to 10ml minimal medium and incubated at 37°C with shaking overnight. In one tube, 
160 µl of bacterial culture was resuspended in 16 ml fresh medium and the contents of one 
Cysticlean tablet was added. For the untreated sample, 100 µl of bacterial culture was 
added to 10 ml minimal medium. A negative control consisted of 10 ml minimal medium 
only. These were incubated for 4 hours at 37°C with shaking. 
16S 
Negative control 
 169 
Resulting bacterial cultures were filtered, firstly through a Whatman 1 membrane, to 
remove the cranberry, and then through a Whatman 0.45 membrane, to allow the bacteria to 
adhere to the filter. 0.45 filters were then placed in 10ml PBS and vortexed at full speed for 
2 mins, to remove the bacteria from the filter. 1 ml of this PBS was removed and 
centrifuged at full speed for 10 mins. The PBS was removed without disturbing the 
resulting pellet, washed with 50µl Phosphate Buffered Saline (PBS) and vortexed to 
resuspend. The suspension was centrifuged again at full speed for 1 min. As much PBS as 
possible was removed and the remaining pellet was placed on ice. 49.5µl of the DNA lysis 
solution and 0.5µl of the DNase solution was added, mixed by pipetting and incubated for 
10 min at room temperature. 5µl of the stop solution was added, mixed by pipetting and 
incubated for 2 mins at room temperature. Extracted RNA was stored at -20°C in aliquots 
and never thawed more than once. RNA stabilizers such as RNA protect, are not required 
with the cells to Ct kit.  
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6.3.5 DNA and RNA Quantification 
DNA and RNA concentration were measured using a Qubit 3 fluorometer (figure 6-IV) 
(Thermofisher Scientific, Paisley, UK).   
 
 Figure 6-IV The Qubit™ kit protocols for the detection of DNA and RNA. dsDNA BR Assay Kit was used to detect the 
concentration of DNA and the Qubit™ RNA HS Assay Kit was used to detect the concentration of RNA. DNA or RNA 
was mixed with the Qubit working solution (1:200 assay reagent with dilution buffer), vortexed and incubated at room 
temperature for 2 min before reading on the instrument. 
 
6.3.6 Determination of Quality of RNA Extracted for RT-qPCR 
In order to determine the quality of RNA extracted, RNA was run on gel electrophoresis 
immediately after extraction. Approximately 2µg of RNA (measured with the Qubit 3 
fluorometer) was mixed with the same amount of RNA loading dye in a Microcentrifuge 
tube. This was then heated in the heat block alongside 4µl of RiboRuler High Range RNA 
Ladder, ready-to-use (Thermofisher, Paisley, UK) in a separate tube, for 10 min at 70°C. 
Both tubes were then placed in ice for 3 mins and spun briefly using the Labnet Prism mini 
centrifuge (Fisher Scientific, Loughborough, UK) before being loaded onto a 1% agarose 
gel (made using protocol in 6.5.3) and run at 110 volts for 60 mins.  
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6.4 Primer Design 
6.4.1 End-Point PCR 
Primer sequences were found using NCBI GenBank (National Center for Biotechnology 
Information, Bethesda, USA) and primers were designed using the Primer-Blast tool. 
Primer-Blast can be accessed here: https://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi. GenBank can be accessed here: https://www.ncbi.nlm.nih.gov/genbank/. 
Primers were then checked for specificity by the BLAST blastn suite (National Center for 
Biotechnology Information, Bethesda, USA). BLAST can be accessed here: 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&PROG_DEF=blastn&
BLAST_PROG_DEF=megaBlast&SHOW_DEFAULTS=on&BLAST_SPEC=MicrobialGe
nomes.  Primers were then checked using the OligoAnalyzer 3.1 (Integrated DNA 
Technologies Inc, Illinois, USA) for self-dimers, heterodimers, hairpins, GC content, 
annealing temperature and palindromes. The OligoAnalyzer can be found here: 
https://eu.idtdna.com/calc/analyzer. In general, primers for end-point PCR should be 18-22 
bp in length, have a GC content of 40-60% and the forward and reverse primers should 
have similar annealing temperatures. Primers for multiplex PCRs were also ran through the 
ThermoFisher Multiple Primer Analyzer, to check for primer-dimer formation. The 
Multiple Primer Analyzer can be found here: 
https://www.thermofisher.com/uk/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-
scientific-web-tools/multiple-primer-analyzer.html.  
 172 
Primers were ordered from Integrated DNA Technologies, at a concentration of 25 nm, and 
diluted with sterile distilled water to 100 µM concentrations.  
6.4.2 Qualitative Real-Time PCR – Plexor 
Primers were adapted from (Singh, et al., 2016). Iso-dC and fluorescence labels were added 
to each of the forward primers using the IDT custom DNA oligos website (Integrated DNA 
Technologies Inc, Illinois, USA). Forward primers were ordered at a concentration of 100 
nM and purified by HPLC. Reverse primers were ordered at a concentration of 25 nM with 
standard desalting. All primers were diluted to 100 µM with MOPS/EDTA buffer (supplied 
with Plexor qPCR System, Promega, Southampton, UK).  
6.4.3 RT-qPCR – Taqman 
Taqman chemistry was chosen for its high specificity, when compared to SYBR green. 
qPCR primers and Taqman probes were designed using the PrimerQuest Tool (Integrated 
DNA Technologies) using custom design parameters. Primers were designed to be 20-24 
bp, with a melting temperature of approximately 60 °C. The GC content was designed to be 
40-60%, however ideally it should be 50%. Ideally, the last five bases should be made up of 
3 A/T and 2 G/C. Taqman probes were designed to be 20-30 bp in length, with a melting 
temperature of 7-10 °C higher than that of the primers, with a GC content of 35-65%. The 
5’ end of the probe should ideally be around 5 bases away from the 3’ end of the forward 
primer. A G base should be avoided at the 5’ end. Ideally the probe should have fewer Gs 
than Cs. Both primers and probes should avoid >4 repeats of the same base e.g. 
AAAAAAAA, as well as palindromes e.g. AGGAGGAGGA. The amplicon should be 
small, around 70-150 bp. The OligoAnalyzer 3.1 was used to identify and possibility of 
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secondary structure and primer dimers. Whilst non-specific products do not produce results 
in Taqman qPCR, they should be avoided as they reduce the efficiency of the reaction. The 
FAM fluorophore was added to the 5’ end of the probe and the Black Hole Quencher®-1 
was added to the 3’ end using the custom DNA oligo tool (Integrated DNA Technologies). 
Probes were ordered as a 100nm scale and purified by HPLC. Primers were ordered as a 
25nm scale by standard methods. Both primers and probes were ordered as “lab ready”, 100 
µM in IDTE, PH 8.0.  
6.5 Development and Optimisation of PCR Assays 
6.5.1 Detection of the ESBLs: TEM, SHV, OXA, CTX-M 
As the end-point PCR machine does not have a gradient PCR option to help determine the 
optimum annealing temperature of multiplex primers, touchdown PCR was used to aid 
optimization of the first assay. Optimisation of primer concentration was achieved by 
means of a primer concentration gradient using the format in figure 6-V. A 400 nM final 
concentration was determined to give optimal results.  
 
Figure 6-V Primer concentration gradient plate format. Primer concentration gradient was used to optimise the 
concentration of both the forward and reverse primers.  
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 DNA concentration was also optimized and a range of 1 µl to 2.5 µl was tried. It was found 
that 2.5 µl gave the best results (figure 6-VI). This could be because colonies were used 
rather than purified DNA. 
The PCR amplification protocol was adapted from (Al-Mayahie, 2013) with the addition of 
touchdown annealing temperatures.  
 
 
Figure 6-VI Agarose gel showing multiplex PCR results for TEM, SHV, OXA and CTX-M primers. DNA was isolated 
from the control isolates obtained from Public Health England. All genes were detected at the expected bp size. Neg 
indicates the negative sample and no bands were observed. M indicates the DNA ladder used, GeneRuler 50 bp DNA 
Ladder (Thermofisher, UK). Products and ladder ran on 2% Agarose gel. 
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6.5.2 Multiplex PCR-based Replicon Typing 
Detection of plasmids was by means of adapting the replicon typing assay designed by 
(Carattoli, 2005). The annealing temperature was raised from 60°C to 65°C and the 
extension time in each cycle was reduced from 1 min to 30 sec. Results can be seen in 
figure 6-VII. 
 
Figure 6-VII Plasmid replicon-typing of control ESBL producing isolates by multiplex PCR. Plasmid DNA was isolated 
from the control isolates obtained from Public Health England (table 1). Plasmids INC N, INC FIA, INC FII and INCI1 
were detected in three of the control bacterial isolates (CTX-M, OXA, SHV), however, no plasmid was detected in the 
control TEM bacterial isolate. INCL/M was only detected in the control SHV bacterial isolate, all genes were detected at 
the expected bp size. M indicates the DNA ladder used, GeneRuler 50 bp DNA Ladder (Thermofisher, UK). Products and 
ladder ran on 2% Agarose gel. 
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6.5.3 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to analyse the results of PCR products. A 10x 
Tris/Boric Acid/EDTA (TBE), Nucleic Acid Electrophoresis Buffer (BioRad, Hertfordshire, 
UK), diluted to 1x with distilled water, was used for gel electrophoresis. The Sub-Cell® GT 
Cell gel tank was used to carried out the electrophoresis.  UltraPure™ Agarose, 
(ThermoFisher Scientific, Paisley, UK) was mixed with the SYBR™ Safe DNA Gel Stain 
in 0.5X TBE to make the following percentages and melted carefully using a microwave. 
To decide upon the percentage of gel required, the table below was used.  
 
Table 6-3 Agarose concentrations used for electrophoresis gels.  Concentrations of agarose used for electrophoresis in this 
study, the amount of agarose required to achieve this concentration in a 50 ml gel and the range of resolution each 
concentration is suited to. 
Agarose concentration 
(w/v%) 
Resolution Range Agarose for 50 ml gel (g) 
0.8 500bp-12kb 0.4 
2 400bp-10kb 0.5 
1.5 200bp—bp-4kb 0.75 
2 100bp-2kb 1 
4 10bp-400bp 2 
 
A total of 5 µl of PCR product was loaded into each well. Loading buffer was not required 
for the end-point PCR products, as the 5x green buffer contained in the GoTaq® G2 DNA 
Polymerase kit (Promega, Southampton, UK) acts as a suitable loading buffer.  
Different voltages and times were required for different products. Generally short 
amplicons were run on a high voltage for a short amount of time. For reactions containing 
multiple products, i.e. multiplex PCR, gels were run at a low voltage and long length of 
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time to optimise resolution of products. The gels were visualised using a Gel Doc EZ 
(BioRad, Hertfordshire, UK) with the Image Lab software (BioRad, Hertfordshire, UK). 
6.6 Qualitative Real-Time PCR - Plexor 
Qualitative real-time PCR conditions such as annealing temperature, primer concentration 
and DNA concentration were optimised using the protocol laid out in 6.5.1 in simplex 
(figure 6-VIII), and once satisfied, in multiplex (figure 6-IX). The amplicons of the control 
isolates were initially tested using high resolution melting curve analysis, first in simplex 
and then multiplex to determine the melting point of the amplicons.  
 
Figure 6-VIII Example melt curve analysis from Real-time PCR for the CTX-M primers in simplex reaction. One clear 
peak indicates only one product was produced during the reaction. RFU relative fluorescence units. 
 
 
 
 
 
 
Figure 6-IX Example melt curve analysis from real-time PCR results for the CTX-M primers in multiplex reaction. One 
clear peak indicates only one product was produced during the reaction. RFU relative fluorescence units. 
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The high-resolution melt curves gave a temperature to use for the simultaneous detection 
method. Initially, 2 °C increments after the annealing stage was used. An increase in 
temperature increments between 84°C and 86°C was implemented to aid resolution 
between the amplicon melting points of CTX-M and TEM as they were quite similar. It was 
found that simultaneous detection before cycle 16 was unnecessary, and so it was removed. 
In the initial stages, DNA extracted by methods explained in 6.3.3 was used, and then DNA 
extracted from colonies, outlined in 6.3.1 were used instead. Results were compared and no 
significant difference was seen. This meant that DNA extracted from colonies used in 3.1.1, 
could be used in this experiment, rather than extracting purified DNA from all the patient 
isolates.  
The results for the development of the qualitative real-time PCR were ran on an agarose 
gel, which can be seen below.  
 179 
 
Figure 6-X Agarose gel results for the multiplex qualitative real-time PCR assay. All genes were detected at the expected 
bp size. 1 band was observed for each primer pair indicating primer specificity. M indicates the DNA ladder used, 
GeneRuler 50 bp DNA Ladder (Thermofisher, UK). Products and ladder ran on 2% Agarose gel. 
 
Results for patient isolates were compared to results achieved previously by phenotypic 
testing and multiplex end-point PCR. 
6.7 Development of RT-qPCR assay  
6.7.1 Minimum Inhibitory Concentration for RT-qPCR 
In order to determine the concentration of cranberry to use in the RT-qPCR experiment, the 
minimum inhibitory concentration was determined. The macrodilution method was used in 
this study. Five tablets were dissolved in 20ml minimal medium (M9 Minimal Salts, 5X, 
Sigma Aldrich, Dorset, UK) to create a 60mg/ml stock solution. Minimal medium was 
chosen as it contains a limited amount of nutrients, aiming to simulate the urinary tract 
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environment. This was then serially diluted in duplicate to produce the following 
concentrations: 30, 15, 7.5, 3.75, 1.87, 0.93, 0.46, 0.23, 0.11, 0.05, 0.03 mg/ml.  
Two single colonies were added to 10 ml minimal medium and 100 µl was added to each 
dilution. A positive control consisted of minimal medium and E. coli. A negative control 
consisted of minimal medium only. All dilutions were incubated overnight at 37°C with 
shaking. Each dilution was then plated out on MacConkey agar and grown for 24 hours at 
37°C. Growth was compared between dilutions and positive control. 
6.7.2 Choice of RT-qPCR Method 
The Cells-to-CT™ 1-Step TaqMan™ Kit was chosen for the RT-qPCR method. This kit 
performs expression analysis from cultured cells, without extensive RNA purification. The 
mastermix contains a reverse transcriptase, allowing for a 1-step RT-qPCR. Laborious 
cDNA conversion is eliminated, as RNA is the input material into the qPCR reaction. The 
Cells-to-CT™  mastermix contains reverse transcriptase, allowing cDNA conversion during 
qPCR. Reducing the number of steps in a protocol, reduces the chances of contamination or 
handling errors. The whole process can be carried out in a single tube, which also reduces 
chance of contamination. Applied Biosystems have compared their product against purified 
RNA and found that the performance was equivalent.   
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6.7.3 Primer Specificity  
RT-qPCR primers were checked for specificity by end-point PCR using extracted DNA 
mentioned in 6.3.3 (figure 6-XI). The presence of primer dimers in addition to the band of 
interest on gels was accepted, as they do not produce results in RT-qPCR, however they 
were avoided as much as possible as they reduce the efficiency of the reaction. Cycling 
parameters were as follows: initial denaturation at 95 °C for 20 s, followed by 40 cycles of 
95 °C for 15 sec and 60 °C for 1 min. 
 
Figure 6-XI Agarose gel results for the primer specificity for the genes investigated by RT-qPCR. DNA was isolated from 
the CTX-M control isolate obtained from Public Health England. All genes were detected at the expected bp size. 1 band 
was observed for each primer pair indicating primer specificity. M indicates the DNA ladder used, GeneRuler 50 bp DNA 
Ladder (Thermofisher, UK). Products and ladder ran on 4% Agarose gel. 
 
6.7.4 No Reverse Transcriptase 
A no reverse transcriptase control was used in triplicate by adding Taqman RT-qPCR mix 
after the reverse transcription step in the PCR cycle, therefore this RNA had not undergone 
cDNA conversion.   
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6.7.5 Validation of Reference Genes 
Six genes (16S, RecA, idnT, cysG, hcaT and idfB) were chosen for potential suitability as a 
reference gene by running qPCR with treated and un-treated samples in triplicate. A change 
in Ct between the untreated and treated samples of less than 0.5 was accepted. Only one 
gene (16S) was determined as a suitable reference gene. Due to time constraints, no more 
genes were tested for suitability as reference genes. The five genes that had failed as 
reference genes, were then treated as genes of interest or discarded.  
6.7.6 Primer Efficiencies 
Primer efficiencies were calculated using serial dilutions of amplicons (diluted 1:1000) in 
triplicate and by plotting the resulting data to produce standard curves for each primer set 
(figure 6-XII). The amplification efficiency = [10(-1/slope)] – 1. A correlation coefficient 
(R2) of 0.99 or greater was preferred. An amplification efficiency of 80-120% was 
preferred. The efficiency of figure 6-XII below was 118.9%. 
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Figure 6-XII Example standard curve for the HcaT gene primers.  Primer efficiencies were calculated using serial 
dilutions of amplicons 1:1000. In this example two anomalies were removed from the calculations. 
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Table 6-4 The efficiencies of the primers used in the development of the RT-qPCR study Primer efficiencies were 
calculated using serial dilutions of amplicons 1:1000. An efficiency of 80-120% was accepted.. 
 
Primer Efficiency % 
16S (reference gene) 84.3 
RecA 111.1 
CTX-M 99.7 
SAT 111.6 
TraT 94.3 
ChuA 115.6 
KPSM 101.7 
SoxS 103.0 
USP 90.2 
HcaT 118.9 
IhfB 115.3 
 
6.8 Choice of Statistical Methods 
6.8.1 Prevalence Study 
It was determined that my data was non-parametric, and I was looking to test for frequency 
distribution of my ESBL types, therefore the Chi squared test was chosen. The Spearman 
Rank Correlation test was chosen for its ability to investigate relationship between the 
ESBL types and plasmids.  
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6.8.2 Qualitative Real-Time PCR assay 
Calculating the sensitivity, specificity and likelihood ratios for a new diagnostic method is 
common practice in the field. A number of journals request that this has been completed 
before submitting a paper suggesting a new diagnostic method.  
6.8.3 Statistical Analysis of RT-qPCR 
6.8.3.1 Modified delta delta Ct method 
The ∆∆Ct equation was used with a modification to account for primer efficiencies. The 
equation can be found below.  
6.8.3.2 Abbreviations 
Average Ct = AvCt 
Average Ct taking into account efficiency = AvCtE 
Change in Ct = ∆Ct  
6.8.3.3 Calculations 
𝐴𝑣𝐶𝑡 =  
𝑟𝑎𝑤 𝑑𝑎𝑡𝑎 1 + 𝑟𝑎𝑤 𝑑𝑎𝑡𝑎 2 + 𝑟𝑎𝑤 𝑑𝑎𝑡𝑎 3
3
 
𝐴𝑣𝐶𝑡𝐸 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑡 ∗  (log
(1 +
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
100 )
(log(2))
) 
 
∆𝐶𝑡 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 = 𝐴𝑣𝐶𝑡𝐸 (𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙)𝑓𝑜𝑟 𝑔𝑒𝑛𝑒 𝑏𝑒𝑖𝑛𝑔 𝑡𝑒𝑠𝑡𝑒𝑑 −
𝐴𝑣𝐶𝑡𝐸 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)𝑓𝑜𝑟 𝑔𝑒𝑛𝑒 𝑏𝑒𝑖𝑛𝑔 𝑡𝑒𝑠𝑡𝑒𝑑  
 
 186 
∆𝐶𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 = 𝐴𝑣𝐶𝑡𝐸 (𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙)𝑓𝑜𝑟 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒 −
𝐴𝑣𝐶𝑡𝐸 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)𝑓𝑜𝑟 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒  
 
∆∆𝐶𝑡 =  ∆𝐶𝑡 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − ∆𝐶𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =  2^∆∆𝐶𝑡 
6.8.3.4 T-test 
Data was determined to be parametric, and independent. Therefore, the independent t-test 
was applied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
